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A 7-year-old child was found to contain <1% of factor XII (FXII) activity. 
FXn is one of the factors in the intrinsic pathway of coagulation, fibrinolysis and 
complement system, the deficiency of which in human may lead to high risks of 
venous thromboembolic disease or myocardial infarction. The parents ofour patient 
have 29% and 36% of FXII activity level while his brother has 43% FXII activity ‘ 
level. From previous studies of FXII deficiency in Caucasians, most mutations were 
found in the catalytic domain ofthe FXII gene located in chromosome 5. Based on 
this, we first checked the sequence ofexon 10 to exon 14 which encode the catalytic 
domain. These five exons were amplified by PCR using appropriate primers which 
initiated the amplification of every two sequential exons plus the intron between 
them. The PCR products from the patient and wild type were sequenced by cycle 
sequencing, using ^^P-labelled PCR primers. Five exons in a total of 1942 bp were 
sequenced. No mutation was found in the catalytic domain of the FXII gene of the 
patient. Since the additional TaqI restriction site which was mapped in intron B of 
FXII was reported to be associated with FXII deficiency, we have also amplified 
intron B from a normal person and the patient. The resulting PCR products were 
digested by TaqI restriction enzyme but no additional TaqI digestion site was found. 
Factor XII is expressed in the liver but a previous study showed that the ectopic 
transcript ofFXII could be detected by RT-PCR in the peripheral blood lymphocytes. 
By using a pair ofprimers located in exon 2 and exon 4 of the FXII gene, we found 
that ectopic transcripts were detected in the peripheral blood lymphocytes as well as 
bone marrow of a normal person but not in the patient's peripheral blood 




The failure in detecting ectopic transcripts of FXII in the patient may be due to the 
mutation in the 3’ end untranslated region which is related to the mRNA stability. 
The 3, end untranslated region of the factor XII gene was amplified by PCR and 
sequenced. However, no mutation was found. Furthermore, the probable molecular 
defects may also be in the promoter region or in the transcriptional regulatory 
control. To localise the molecular defect in the promoter region, the 3 kb long 5, 
flanking region ofthe factor XII gene was amplified by 5 pairs of primers, with each 
pair yielding a 600-800 bp product. The PCR products were sequenced by cycle 
sequencing and no difference in the nucleotide sequence was detected between the 
patient and the normal person. Incidentally, we have found several discrepancies 
between our nucleotide sequence with the GenBank database in the promoter region. « 
The most striking one was a 95 bp insertion located between nucleotide number 829 
and 830 in the 5'-end region. This additional sequence was found in the patient, his 
family members and 12 other normal persons, including 3 Caucasians and 4 
Pakistanis. By searching the TRANSFAC database, we have identified several 
putative protein binding sites in the 95-bp novel sequence. The binding of one of 
these proteins, called Yin Yang-1 (YY-1), was studied by gel mobility shift assay. 
However, the 95-bp novel sequence was not bound by YY-1 protein in vitro. Future 
studies may be focused on the short arm of chromosome 6 as well as the exon 1 - 4 
and the 3, flanking region of the FXII gene, in which possible mutations causing 
FXn deficiency in our patient may be found. 
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a) Blood Coagulation 
Blood coagulation is an important component ofhost defence mechanisms. It 
involves the sequential activation of multiple zymogens by limited proteolysis, 
leading to the thrombin generation and conversion of soluble fibrinogen to insoluble • > ‘ 
fibrin. These reactions are dependent on the cell-cell interaction such as platelet-
‘ 
platelet and platelet-endothelial cell interaction, as well as interactions of other 
components in the vessel wall. 
The waterfall hypothesis of blood coagulation was proposed by Davie and 
Ratnoff (1964) and Macfarlane (1964). The hypothesis stated that the fibrin 
formation was the result of a series of stepwise reactions involving clotting factors 
circulating in blood in a precursor or zymogen form (fig 1). After limited 
proteolysis, zymogens are converted to active two-chain serine proteases. The 
hypothesis also divided the events ofcoagulation into extrinsic pathway and intrinsic 
pathway. The extrinsic pathway consists of factor VII and tissue factor. Factor VII, 
when activated, forrns a complex with tissue factor that converts factor X to activated 
factor X. The intrinsic pathway, also known as the contact system, consists offactor 
XII, factor XI, factor IX, prekallikrein, high molecular weighted kininogen, and leads 
to the formation offactor IXa which with its cofactor, factor VIIIa, converts factor X 
to activated factor X in the presence of phospholipids and calcium ions. Factor Xa， 
as an active enzyme, forms a complex with cofactor, factor V, and rapidly converts 
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Fig. 1 The coagulation cascade. 
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calcium ions. Once thrombin is formed, it converts fibrinogens to fibrin monomers 
which polymerise to form a insoluble fibrin clot. 
The importance of the platelets and endothelial cell surfaces as the site of 
receptor-mediated clotting reactions in addition to providing the necessary 
phospholipids may be underscored. It now appears that blood coagulation can be 
initiated when tissue factor, expressed after injury to the vessel wall, is exposed to 
factor VII inside the bloodstream. Tissue factor, which is expressed by cells o f the 
adventitia of blood vessels as well as in other tissues throughout the body, is not 
normally found either' in the circulating blood or on the surface of the vascular 
lumen. The endothelial cell barrier normally separates the tissue factor from the 
factor VII. Endothelial cell does not express tissue factor constitutively, unless 
stimulated by other substances such as tumour necrosis factor or endotoxin. Once 
expressed, the tissue factor forms a complex with factor VII. Factor VII is then 
converted to its active form, but the mechanism of this conversion is not clear. One 
prevailing hypothesis is that small amounts ofactivated factor X are always available 
to activate factor VII (Rao et aL, 1986; Masys et aL, 1982). Another hypothesis is - . -- - -- - - - • • 
that factor VII can undergo autoactivation (Pedersen et al., 1989), that is，small 
amounts of activated factor VII are always available to activate the zymogen form. 
Whatever the mechanism of factor VII activation, it is clear that the tissue factor-
factor VIIa complex activates both factor X and factor IX. Once activated factor X 
and activated factor IX are formed, the subsequent reactions amplify the coagulation 
on the surface of platelet surface. The amplification can be due to the positive 
^ 
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feedback of factor X, which after activated by factor VII or factor IX’ can activate 
factorVII. 
The importance ofthis tissue factor initiated reaction can be inferred from the 
severity ofhemophilic bleeding associated with factor VII or factor IX deficiency in 
which the full extrinsic pathway of coagulation is intact and the patients suffered 
from the severe failure of hemostasis. However, factor IX deficiency is a mild 
disorder. Deficiency of other factors in contact system such as factor XII, 
prekallikrein and high molecular weighted kininogen is not associated with bleeding 
but with thrombosis. 
b) The roles offactorXII 
Normally, blood clots quickly when it comes into contact with foreign 
surface. Contact ofblood to foreign surface may not only lead to blood clotting, but 
also increase vascular permeability, lysis of clots and induction of pain. All these 
contact-activated reactions, i.e. blood coagulation (blood clotting), fibrinolysis (lysis 
ofclots) and kinin generation (increasing vessel permeability and inducing pain), are 
triggered by several plasma proteins called contact factors. 
Contact factors include factor XII (FXII, also called Hageman factor), factor 
XI，plasma prekallikrein and high-molecular-weighted kininogen (HMWK). Factor 
XII, factor XI and prekallikrein are serine protease zymogens that, after activation, 
can hydrolyse peptide bonds depending upon the amino acid serine in their active 
centre. HMWK is a precursor ofbradykinin and functions in the contact system as a 
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cofactor. HMWK circulates in blood as a noncovalent complex with prekallikrein 
and factor XI. Once the complex exposes to a negatively charged surface，the 
kininogen binds through its histidine-rich domain. The kininogen-prekallikrein 
complex is rapidly activated by surface-bound a FXIIa. Conversely, kallikrein, 
activated from prekallikrein, activates surface bound factor XII zymogen efficiently 
in the presence of HMWK. Furthermore, kallikrein cleaves HMWK into two 
peptide, one is bradykinin. Bradykinin is a potent vasodilator and also stimulates 
pain fibres, elicits transudation .by increasing vascular permeability, and is a 
chemoattractant for neutrophils (Tuddenham and Cooper, 1994d). 
Surface bound factor XII is activated by the prekallikrein-HMWK complex. 
The binding of factor XII to a surface may induce a conformational change that 
exposes hidden active sites (Samuel et aL, 1992; Saito and Kojima, 1995) and also 
facilitates the cleavage by kallikrein. The limited proteolysis of zymogen results in 
the formation of the a form of factor XII which has the ability to convert 
prekallikrein to kallikrein and factor XI to the active form. The reciprocal activation 
of kallikrein and factor XII is a positive feedback loop that serves to amplify the 
rapid mutual activation of factor XII and kallikrein. Although autoactivation of 
factor XII was found (Tans et al., 1983)，the kallikrein-dependent activation offactor 
• 
XII plays the predominant role in the contact system (Tuddenham and Cooper, 
1994d). 
In the presence of Ca�+，the activated factor XI can convert inactive factor IX 
to active form. Activated factor IX forms a complex with factor VIII and has the 
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ability to activate factor X. In the presence of platelets, Ca�+ and factor V, factor X 
convert prothrombin to thrombin which then convert fibrinogen to fibrin monomer. 
Fibrin monomer then polymerise to form fibrin polymer which is the major 
component of clots. 
> Factor XII can activate coagulation by the activation of factor XI. Factor XII 
can also activate fibrinolysis. Kallikrein activated by factor XII can convert 
plasminogen to plasmin. a factor XII also has the ability to convert plasminogen to 
plasmin, but only in a very slow rate (Candena et al., 1994). The physiological 
significance of the contact activation of fibrinolysis is unclear, because the rate of 
activation is 1% to 4% of the plasminogen activating activity of urokinase (Candena 
et al., 1994). However, the euglobulin fraction of chloroform-treated plasma and 
native hereditary angioedema plasma, which lacks the Cl-inhibitor, contains a 
readily demonstrated nega t ive ly -cha rged - su r f ace -dependen t fibrinolysis activator 
system, which is absent from the factor XII-deficient plasma and normal plasma 
(Tuddenham and Cooper, 1994c; Candena et al., 1994). Chloroform has shown to be 
the inhibitor of Cl-inhibitor which is the important inhibitor of active factor XII 
(Candena et al., 1994). Removal of Cl-inhibitor for plasma allows factor XII 
activated by negatively charged surface to activate kallikrein which converts 
plasminogen to plasmin. 
. The individual with deficiency in the contact factors usually do not bleed 
excessively. Majority of patient with Hageman trait, named by the index patient, 
John Hageman, have high risk for venous thrombosis and myocardial infarction. 
9 
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Lammle et al. (1991) has reported the thromboembolism and bleeding tendency in 74 
individuals subjects from 14 Swiss families. None of 18 factor XII deficient patients 
(FXII:C < 0.01 U/ml) has any abnormal bleeding t endency�A total of 34 surgical 
interventions in 15 of the 18 patient had been performed without any bleeding 
complications. One of 45 heterozygotes had a milding bleed tendency. None of 
remaining 44 heterozygotes and none of 11 normal subjects reported any abnormal 
bleeding. Two of the 18 factor XII deficient patients had suffered from the deep 
venous thrombosis. In a literature review of 121 subjects with factor XII deficiency, 
an 8% incidence ofvenous thrombosis and several incidence of myocardial infarction 
were found (Goodnough et al., 1983). From symptom of factor XII deficient patient, 
factor XII may play a important role in the fibrinolysis activation and there should be 
other pathway by-pass factor XII to activate coagulation. 
Other than coagulation and fibrinolysis, the contact system can activate 
complement and inflammation. Activated factor XII can activate the classic pathway 
of complement by interacting with macromolecular C1. C1 activation by factor XII 
is enzymatic, does not require the participation of either prekallikrein or 
plasminogen. Factor XII activates inflammation by stimulating neutrophil 
aggregation and degranulation. In an in vitro system, neutrophils release elastase 
during blood coagulation, but neutrophils release less elastase when they are 
resuspended in either prekallikrein or factor XII deficient plasma. Besides, factor XII 
also stimulates monocytes to release interleukin 1. 
• 7 
c) Genomic organisation of the human factor XII gene 
The history of chromosomal location of factor XII gene is somewhat 
chequered. Based on the cytogenetic study on factor XII deficient patients, the 
6 
location of factor XII gene was proposed in chromosome 6 and chromosome 7 
(Tuddenham and Cooper, 1994c). After Pearson et al. (1982) observed the reduction 
of factor XII level in an individual with 6p deletion, the location of factor XII gene 
turned back to chromosome 6. However, the use of somatic cell hybrid analysis, the 
factor XII gene was found to be located in chromosome 5 (Royle et aL, 1988; 
Citarella et al., 1988). This was confirmed by in situ hybridisation and ftoher 
narrowed to 5q33-5qter. The location of factor XII in chromosome 5 does not 
exclude the possibility ofother genes located in different chromosomes that influence 
the expression offactor XII. 
The structure of factor XII gene (fig 2) was described by Cool and 
MacGillivray (1987). The genomic factor XII fragment was isolated from a human 
genomic library using factor XII cDNA fragment as the hybridisation probe. After 
sequencing analysis, they found that factor XII gene has 14 exons of approximately 
12 kb. Exon 1 and exon 2 are separated from other exons by 2 large introns with size 
4.5 kb and 3 kb. Exon 3 to exon 14 are located in a genomic region ofabout 4.1 kb. 
The sequencing analysis showed that all introns follow the GT-AG rule of intron 
splicing 03reathnach and Chambon, 1981) except for the donor sequence ofintron J 
which has a GC splicing site instead of GT. The consensus sequences surrounding 
splicing junctions in RNA polymerase II-transcribed genes were also found to be in 
• 
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Fig. 2 Factor XII gene and its protein. The factor XII gene is shown in the upper 
portion and the protein is shown in the lower portion with amino terminus 
at the left and carboxyl terminus at the right. The mRNA of factor XII is 
about 2.4 kb, with about 200 bp poly(A) tail. S: singal peptide; SP: signal 
peptidase; Fn 11: fibronectin type II domain; G: epidermal growth factor-
like domain; Fn I: fibronectin type I domain; K: kringle domain; P: proline 
rich region; C: catalytic domain. The three arrows indicates the cleavage 
site ofkallikrein. (Reproduced from Saito and Kojima, 1995) 
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agreement withthe intron-exonjunctions offactor XII gene (Cool and MacGillivray, 
1987). Cool and MacGillivray (1987) also sequenced 350 bp of the 5'-end flanking 
region offactorXII. Translation starts at the ATG codon. The consensus sequence 
GAC GCC prior to the initiator ATG codon and 18 amino acid residues with 
characteristic hydrophobic core following ATG argues for a signal peptide length of 
19 amino acid residues (Cool and MacGillivray. 1987). By primer extension and S1 
nuclease mapping analysis, the initial transcription site was located at 49 bp upstream 
ofthe ATG initiation codon. Other alternative sites of transcription initiation were 
also reported (Cool and MacGillivray, 1987). The CCAAT or TATA boxes were not 
found in the 5'-end flanking region. The blood coagulation factors as well as many 
other genes have atypical TATA box or are lacking of canonical TATA box. Other 
genes such as some housekeeping genes do not have TATA box but contain GC rich 
region 5' to the transcriptional start site. It seems that the major role ofTATA box is 
to direct the position of the 5,-end of transcript. Furthermore, the absence of 
CCAAT and TATA boxes in factor XII gene is also consistent with the finding that 
. ‘ ~ • — ^ . ^ • ‘ 
transcription of the gene may be initiated at multiple sites. Cool and MacGillivray 
suggested that the absence of the CCAAT or TATA boxes may be a means of 
maintaining a low level of transcription. The ATG GTA GT sequence which is 
similar to the SV40 enhancer core consensus sequence is located in the factor XII 
gene at -330 bp. Three Alu I repeat sequences have been identified by Cool and 
MacGillivray (1987). One was found at -370 bp upstream the transcription initiation 
site. The other two were found in intron B. 
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The 5, regulatory sequence ofhuman factor XII gene was further studied by 
Citarella et al (1993). The sequenced region was up to 3077 bp upstream of the 
transcription initiation site. The 5, region was particularly rich in Alu sequences. 
The factor XII promoter containes three GGCGGG regulatory elements which are 
recognised by Spl binding protein (Citarella et aL, 1993). As seen in other TATA 
box-l^ss housekeeping gene, Spl factors may be important for factor XII expression. 
A factor TX silencer (CCTCTCCTG) was identified at position -3011. The liver 
specific transcription factor LF-A1 recognition sequence TGGACC was identified at 
+30 and -2693. The sequence AGGGCAGCTTGACC, present at position -44/-31，is 
homologous except for one nucleotide to the palindrome AGGTCANNNTGACC 
reported as estrogen responsive element (ERE) and in addition three half EREs 
(AGGTCA) were identified at position -1314，-968 and -608 (Citarella et al, 1993). 
The imperfect palindrome of ERE in factor XII was reported to be a regulatory 
element of factor XII expression (Farsetti et al., 1995) by fusing factor XII promoter 
to the chloramphenicol acetyltransferase (CAT) gene. They found that in the 
presence of 17p-estradiol, homologous to estrogen, expression of CAT gene was 
driven by the factor XII promoter. Only 230 bp of the 5'-end flanking sequence of 
factor XII gene were sufficient to�confer hormone-mediated elevation in the 
transcription of the gene. 
The cDNA offactor XII was first isolated from cDNA library ofhuman liver 
by Cool et al (1985). The 1959 bp cDNA was sequenced and analysed. Northern 
hybridisation of liver mRNA to the designed cDNA probe showed that factor XII 
mRNA was about 2.4 kb in length (Cool et a/.,1985). 150 bp of the 3, untranslated 
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region was sequenced and AAT AAA polyadenylation, which is involved in the 
polyadenylation of mRNA, was located at 17 nucleotides upstream of the poly(A) 
tail. The amino acid sequence predicted from the isolated cDNA was in excellent 
agreement with that determined from the purified protein. 
d) Protein structure of the human factor XII 
The factor XII zymogen circulates in plasma with a concentration of about 30 
jig/ml and a half-life time of 50 - 70 hours (Saito 1987). Factor XII zymogen is 
synthesised in liver cells. The mature factor XII protein is 80 kDa, consisting of a 
single peptide chain with 596 amino acid residues and 16.8% carbohydrates. By 
comparing the protein sequence offactor XII with protein sequences in the National 
Biomedical Research Foundation Protein Data Base, the schematic representation of 
protein structure was found (fig 3; Cool et aL，1985). This structure was based on 
five different regions that shared homology with the sequence in tissue plasminogen 
activator or fibronectin. 
The position of introns in the factor XII gene divides the coding region into 
discrete protein modular units (Cool and MacGillivray, 1987). The signal peptide is 
encoded by exon 1. A "type 11” homology with collagen binding properties in 
fibronectin is represented by exon 3 and exon 4. Next is the EGF-like domain in 
exon 5. "Type 1” homology or the fibrin finger in fibronectin is found in exon 6 
which is followed by another EGF-like domain in exon 7. The kringle domain and 
proline-rich region are represented in exon 8 and exon 9. The kringle domain is 
typically 80 amino acids in length and contains three characteristic disulphide bonds. 
-12 
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Similar structure has been found in plasminogen, tissue plasminogen activator and 
urokinase-like plasminogen activator (Cool and MacGillivray, 1987). The proline-
rich region does not share homology with proline-rich regions in other proteins (Cool 
et al., 1985). The catalytic domain and 3, untranslated region are represented from 
\__ 
exon 10 to exon 14. The catalytic domain contains a trypsin-like serine protease 
which is released after kallikrein cleavage. .. 
The activation of factor XII zymogen requires the cleavage of kallikrein at 
Arg353-Val354. The final product is a FXIIa which consists of a heavy chain (52 kDa) 
and a light chain (28 kDa). The a FXIIa possesses the serine protease activity and 
binding activity. The binding activity of factor XII was proposed to be located in the 
fibronectin type I domain and kringle domain (Tans et al.，1987). Pixley et al (1987) 
showed that the surface-catalysed activity of factor XII was inhibited by a 
monoclonal antibody (mAb B7C9) that recognises the fibronectin type I domain. 
Moreover, the kringle domain was demonstrated to have no contribution to the 
surface binding (Ravon et al, 1995). A monoclonal antibody, MoAb F1, was 
showed to be able to activate the contact system in plasma O^uijen et al., 1989). 
Once MoAb F1 was bound to the kringle domain of factor XII，the rate of activation 
of factor XII by kallikrein and by autoactivation was shown to increase by 60- and 
30-fold respectively. However, it was not able to inhibit binding of labelled factor 
XII to negatively charged surface such as glass. Generally, kringle domain was 
thought to play a role in the protein-protein interaction, as observed in the binding of 
plasminogen and aj-antiplasmin (Wiman et al” 1979). The mitogenic effect of 
• 13 
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Fig. 3 Complete amino acid sequence of factor XII. The curved arrow indicates the Arg_ 
Val bond cleaved by plasma kallikrein and after cleavage, a-FXIIa consists ofheavy 
chain (the NH? end) and light chain (COOH end) which contains the catalytic 
domain. These two chains are linked together by a disulphate bridge. The catalytic 
triad in light chain are circled (His40, Asp89, Serl91). The solid diamonds show the 
iV"glycosylation sites, and the open diamonds represent the proposed 0-glycosylation 
sites. Different parts of structure of factor XII protein were homologous to differen 
protein domains. "Type II domain” and “Type I domain，，share sequence homology 
with type II homology region and type I homology region of fibronectin respectively. 
The "finger"-like type I domain may be involved in the surface binding of factor XII. 
Two "Growth factor domain" are homologous to an epidermal growth factor-like 
sequence. After the growth factor domain, there is a kringle domain which is 
followed by proline-rich region (17 out of 52 residues are proline). The final and 
biggest domain is the catalytic domain which contains the active site (Serl91) and 
peptide backbone SWG (Ser213-Trp214-Gly215) which may interact with the side 
chains of the substrate to properly orient the bond that is to be cleaved. (Reproduced 
from Saito and Kojima, 1995) 
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factor XII on HepG 2 cells may be due to the binding to the hepatocyte growth factor 
receptor via the kringle domain (Ravon et aI., 1995). The type 11 homology domain 
. 
is the collagen-binding site in fibronectin and probably also in factor XII. 
Subsidiary cleavage at Arg334_Asn335 and at Arg343_Leu344 convert a FXlla to ~ 
FXIla. > P FXIla contains the entire light chain of a FXIla and a small peptide of 9 
amino acids attached by a disulphide linkage. P FXIla is a potent activator of 
prekallikrein but has lost the abi!ity to activate the surface bound factor XI because ~ 
FXIla lacks the surface binding ability which is in the heavy chain of a FXlla. 
Other than kallikrein activation of factor XII, autoactivation of factor XII was 
also observed (Tans et al., 1983). Autoactivation of factor XII by dextran sulphate 
was reported (Samuel et al., 1992). Factor XII was found to bind DS500 (500 kDa 
dextran sulphate) chain side by side, concurrently with the confonnational change of 
factor XII secondary structure. Then the protein molecule was cleaved and gradually 
relaxed back to its mostly random confonnation. The confonnational change upon 
binding to negatively charged surface (dextran sulphate in vitro or phospholipids in 
vivo) may result in the increase in- susceptible of the factor XII molecule to the 
cleavage of kallikrein or activated factor XII. 
By comparing the protein structure of factor XII with other coagulation 
factors and fibrinolytic factors, factor XII was more similar to fibrinolytic factors 
than to coagulation factors. Furthennore, when the positions of introns of the 
plasminogen genes were compared with those of factor XII, they were found to be 
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more conserved in the C-terminal serine·protease half of the molecules than in the N-
terminal region of the protein (Cool and MacGillivray, 1987; fig 4). The protein-
coding sequence of N-terminal region of the plasminogen activators and factor XII 
are interrupted by introns in identical triplet codon reading frame although there is 
considerable variation in the coding sequence itself. O~ the other hands, the serine 
protease domain of factor XII, tissue plasminogen activator and urokinase-like 
plasminogen activator consists of five exons which are flanked by introns that have 
inserted into the same triplet codon reading frame in all three gene (Cool and 
MacGillivray, 1987). The organisation was compared with other serine proteases in 
order to determine the evolutionary history of factor XII gene. Serine proteases can 
be divided into 5 families, based on the intron-exon gene organisation. It was found 
that factor -XII is closely related to the plasminogen activator, pancreatic nerve 
growth factor and kallikrein family of serine proteases since each of these genes • 
contain introns 3' to the codons for both the active site histidine and aspartate and 
contain a 5' intron to the codon for the active site serine. However, factor XII is 
more closely related to plasminogen activator because all four introns are placed· in 
almost same location and in the same codonphase in the genes (Cool and 
MacGillivray, 1987). 
e) Mutations in factor XII 
Genetic diseases of coagulation factors are often hereditary. Point mutation, 
frame shift mutation and other chromosomal abnormalities · such as deletion, 
translocation and insertion may cause genetic diseases by altering or even abolishing 
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Fig4. Comparison of exon organisation of catalytic domain of different serine 
j proteases. The exons are shown as open boxes. Triplet codon phase in which 
1 the intron is positioned is represented as 0, I, II. The activation sites of the 
I zymogen are shown by an arrow. The codon of histidine, aspartic acid and 
j serine residue comprising the catalytic triad are indicated by H, D and S 
\ respectively. The slashed bars represent the 3, end untranslated region of 
mRNA. (Reproduced from Cool and MacGillivray, 1987). 
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the activity of the gene product. Each type of mutations may occur in the coding 
region, within the intron or in the mRNA splicing junction. These mutations may 
alter or encompass a specific sequence- which performs a struc~al or regulatory 
functions. Whatever the type of mutation and wherever the mutation occurs, 
mutation may interfere in any stage in the pathway of expression of a gene to the 
protein' product and hence abnormal phenotype is shown. 
Point mutation in a gene may be a substitution of a single base which can be a 
transversion, that is, the substitution of purine by another purine ( C ~ G or A -7 T), or 
can be a transition, that is, the substitution of purine by pyrimidine or verse vice 
(A-7G or C-7T). This kind of mutation may cause the change of an amino acid 
residue after translation and the protein may lose its function if the changed residue is 
important for the conformation of the protein or for the activation or is in the 
catalytic centre. Otherwise the protein may function normally. For example, the 
GAA -7 GT A mutation in exon 1 of factor VIII caused the substitution of glutamic 
acid by valine (Tuddenham and Cooper, 1994a). Point mutation may also be an 
insertion or deletion of a base (sometime both). Both insertion and deletion may 
.cause the frameshift mutation, that is, the reading frame is shifted one base or two 
resulting the translated product being totally different to the original one. For 
example, Bottema et al. (1989) reported a 4 bp insertion in the factor IX gene in a 
patient with severe hemophilia B. Or, if a point mutation .occur in the mRNA 
splicing junction, alternative mRNA will be produced after mRNA processing. 
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Chromosomal abnormalities such as deletion, inversion, insertion and 
translocation are also observed in genetic diseases. For example gross deletion 
appear to make up of 8% ofhemophilia B and the size of deletion varies from as little 
as a single base to over 270 kb (Tuddenham and Cooper, 1994b). However, none of 
this type of gross mutation was reported in the factor XII g e n e � A l l reported 
mutations were point mutations. 
Factor XII deficiency is autosomal recessive. The majority ofcases offactor 
XII deficiency have absent immunoreactive factor XII antigen in plasma but a few 
CRM^ variant (cross-reacting material positive variant, that is，the plasma contains 
non- functional and immunologically identifiable factor XII) have been found and 
characterised. One of the CRM+ variant was called FXII Washington D.C. (Miyata 
,t al., 1989). FXII Washington D.C. had same molecular weight and same 
specificity to antigen as the normal factor XIL However, FXII Washington D.C. 
showed no activity in the initiation of coagulation. By amino acid analysis and 
sequence determination, cysteine in residue position 571 was substituted by serine 
(fig 5). Cys-571 normally forms the disulphide linkage with Cys-540. Cys-571 and 
Cys-540 are highly conserved amino acid residue among serine proteases. The 
disulphide linkage is exposed on the surface, so-called serine disulphide loop，and 
lies close to the specificity hole. Its integrity is probably important for the enzyme 
activity. The loop contains the active site serine residue (Ser-195) and residues 
Ser214-Trp215-Gly216 which is thought to interact with the side chains of the 
substrate to properly orient the bond that is to be cleaved. The Cys + Ser 
substitution in FXII Washington D.C. variant destroys the formation of disulphide 
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linkage between Cys-571 and Cys-540, altering the conformation of the active-site 
serine residue or the secondary substrate-binding site, which leads to loss of the 
enzyme activity. As the genetic coding of cysteine is TGT, the genomic sequence 
encoding for FXII Washington D.C. has AGT or TCT nucleotide mutation. The 
second characterised CRM+ variant was called FXII Locamo (Wuillemin et aL, 
1992): Under the reducing condition, FXII Locamo showed its size of 80 kDa after 
dextran sulphate activation while the normal FXII was 50 kDa. Therefore, FXII 
Locamo was not cleaved by kallikrein upon dextran sulphate activation. 
Furthermore, FXII Locamo focused at about 0.2 pH unit lower than normal FXII in 
isoelectric focusing. The difference was assumed to be the substitution of a basic 
amino acid by a neutral amino acid, or of a neutral amino acid by an acidic amino 
acid. The substitution altered the structure and prevented the cleavage of kallikrein, 
and therefore, the catalytic centre could not be expressed. Further investigation of 
FXII Locamo by Hovinga et aL (1994) showed that by amino acid sequencing, Arg 
353 was substituted by proline (fig 5). Because the genetic code of arginine is C G C， 
most likely a single base mutation of CCC has occurred in the genomic DNA of FXII 
Locamo. Since the FXII Locamo was not activated by kallikrein upon binding to 
negatively charged surface, it was proposed that the cleavage by kallikrein at Arg 353 
_ Val 354 is essential to expose the catalytic active site in normal FXII (Hovinga et 
aI., 1994). 
Another characterised variant was called FXII Bem (Wuillemin et aL, 1991). 
This variant has the same molecular weight of 80 kDa as normal protein and same 
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321 331 341 351 361 371 
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Normal ALPAKREQPPSLTRNGPLSCGQRLRKSLSSMT^VGGLVALRGAHPYIAALYWGHSFCAG 
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1^ ^ Exon 10 
381 391 401 411 421 431 
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> 丨 < Exon 11 
、 441 451 461 471 481 491 




_ ^ | ^ Exon 12 > \ < 
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Exon 13 > - K 
561 571 581 591 
i I i i 
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Washington DC S 
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Exon 14 ^ 
Fig 5. The amino acid sequence of the catalytic domain of the normal human factor XII 
protein and other two variant proteins, FXII Washington DC and FXII Locamo. 
The FXII Washington DC has the mutation Cys571 -> Ser. The FXII Locamo 
has the mutation Arg353 •> Pro. The amino acid residues coded by different 
exons are shown. 
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isoelectric points 姊 5.9 to 6.8) as normal protein. Adsorption of kaolin was 
identical for both variant and normal protein. In the presence of dextran sulphate and 
exogenous plasma kallikrein, the variant was cleaved with same rate as normal 
protein. But the activated FXII Bem was not able to activate factor XI and 
prekallikrein. Therefore, the defects of the variant was due to the lack of protease 
i “ 
activity> which is located in the light chain of activated factor XH. 
Schloesser et al. (1995) reported the detection of a novel mutation in the 
factor XII mRNA from peripheral blood lymphocytes. After sequencing analysis， 
the mutation was confirmed in the 3'-splicing acceptor site of exon 14. The sequence 
ccgacccagGGTGATT is changed to ccgacccaaGGTGATT (lower case is intronic 
sequence), thereby moving the acceptor site one base downstream and causing the 
reading frame of exon 14 to shifte one nucleotide downstream. The mutated allele 
resulted in detectable transcript but unstable protein. Normally, factor XII is 
expressed in liver cells. However, in this study, the ectopic transcribed mRNA of 
factor XII was detected in the total RNA of peripheral blood lymphocytes. The 
ectopic transcript was reported by Sarkar and Sommer (1989) and Chelly et al 
(1989). Sarkar and Sommer (1989) reported the detection of blue pigment gene, 
factor IX gene, phenylamlanine hydroxylase gene and tyrosine hydroxylase gene 
ectopic transcripts in blood, liver, and even in K562 leukemia cell by RT-PCR. 
Chelly et al. (1989) reported the detection of anti-Miillerian hormone gene, p_globin 
gene, factor VIIIc gene and aldolase A gene ectopic transcripts in different cell lines 
and tissues. The result suggested that any gene may be transcribed at a very low 
level in any cell type (Chelly et al, 1989). The possible explanation of ectopic 
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transcription in _ cell type is that even though in the absence of tissue specific 
transcriptional factors (which enhance the transcription rate), all promoters could be 
minimally active when some ubiquitous transcriptional factors (e.g. TATA box 
factors, RNA polymerase, CAAT box binding proteins) reach their cognate DNA 
elements (Chelly et aL, 1989). No matter how the mechanism of ectopic • 
transcription, the ability of detecting basal level of tissue specific mRNA in easily 
accessible cell such as peripheral blood lymphocytes provides a alternative way to 
investigate the pathological transcript by RT-PCR. Using the ectopic transcript to 
detect gene mutation was demonstrated by Rininsland etal. (1992) who found exon 
21 ofDuchenne muscular dystrophy (DMD) gene deletion by simply performing RT-
PCR. As similar in DMD gene, the ectopic transcript of factor XII is a useful means 
to investigate the mutation. 
An additional TaqI cutting site was first detected in two brothers lacking any 
detectable factor XII protein and also found in other 11 members of their patemal 
lineage (Bemardi et aL, 1987). However, this restriction fragment length 
polymorphism was absent in normal unrelated individuals. The association ofRFLP 
of TaqI and factor XII deficiency suggested that the mutation of the additional 
cutting site could be a gene lesion rather than a meaningless variant. The 
polymorphism was not due to gene deletion, as demonstrated by digestion of other 
restriction enzymes. Therefore, single base mutation was proposed (Bemardi et aL, 
1987). Further study of TaqIBJ^L? showed that the polymorphism was found in five 
individuals with factor XII deficiency, two were sister, and the additional TaqI was 
localised at the larger intron B (between exon 2 and exon 3), about 50 bp from the 3, 
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splicing junction (Bemardi et aL’ 1988). The Taql RFLP probably was part of an 
additional splicing site or only represented a tightly linked polymorphism associated 
with factor XII deficiency. 
By sequencing analysis, Hofferbert et aL (1996) showed that the additional 
TaqI was due to the transition of T to C at 224 bp upstream of the exon 3 and this 
polymorphic site was inside the Alu repeat element that has been characterised as a 
member ofsubfamily SbO. RT-PCR analysis ofthe ectopic transcript offactor XII in 
patient with the T ^ C transition and normal control revealed the products of same 
size and thus this transition did not contribute to additional splicing site. The 
regulatory function of Alu sequences has been reported by Vansant and Reynolds 
(1995). The additional TaqI cutting site is part of the hormone responsive element 
and also part o f B box promoter ofAlu gene (Hofferbert et aL, 1996). Interestingly, 
the mutant sequence with the T � C transition is closer to consensus than the wild 
type sequence. This mutant sequence could be bound with the pol III transcriptional 
factor TFIIIC more effectively than wild type. However, it could block the binding 
of nuclear transcriptional factor such as estrogen receptor to various hormone 
responsive elements and could thus inhibit transcription. After tother analysis of 
gene sequence to 5’ regulatory region, a novel mutation G ^ C transversion 8 bp 
upstream the transcription initiation site was detected. The G 今 C transversion was 
only found in the patients with T 今 C transition. However, this mutation was not 
part of factor XII transcript and also no putative regulator element was found. Which 
oftwo mutations，T •> C in intron B or G � C in 5, regulatory region is pathological 
remains unclear (Hofferbert et al., 1996). 
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f) Methods to detect mutation 
Detection ofthe deletion ofagene, or deletion within the gene, or insertion or 
substitution can readily achieved by Southern hybridisation because the size of 
restriction fragment generated by restriction enzyme digestion will be altered or 
completely removed in the gel electrophoresis. However, this method is not suitable 
to detect single base mutation if the mutation does not alter the restriction enzyme 
cutting site. A l t e m a t i v e method called polymerase chain reaction (PCR) can be 
applied. A pair of primers which are complementary to opposite strand of a given 
DNA template and flanking to the target region of interest can be used to direct the in 
yitro DNA synthesis by PCR. The size of the PCR product exhibits deletion or 
insertion within the gene sequence. Because of the amplification property of PCR, 
PCR will always be performed to obtain sufficient amount of DNA before other 
mutation detection methods are performed. 
• - - - • • 
One of the mutation detection methods is the enzymatic cleavage of 
heteroduplexes. First of all，duplex of RNA-RNA hybrid or RNA-DNA hybrid was 
formed. Ifthere is a mismatch present in the duplex, ribonuclease A will cleave that 
point. The final product will be examined by electrophoresis. Any mismatch 
between the normal and mutant can be revealed by the pattem of electrophoresis. 
The limitation ofthis method is that cloning and in vitro transcription are necessary, 
both are time-consuming. 
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Another similar method is the chemical cleavage ofDNA heteroduplexes in 
which chemical agents such as carbodiimide, hydroxylamine and osmium tetroxide 
are used. Carbodiimide binds to G and T nucleotide in the point of mismatch and 
anti-carbodiimide antibody binds to carbodiimide so that the mobility of a 
mismatched heteroduplex is decreased when compared to the reference homoduplex 
on a nondenaturing polyacrylamide gel. Hydroxylamine and osmium tetroxide 
modify the mismatched C or T nucleotide and piperidine can be used to cleave the 
modified base. However, both enzymatic cleavage and chemical cleavage cannot 
detect all mutation, as reported by Theophilus et al (1989). 
The method of denaturing gradient gel electrophoresis also relies on the 
differences in the behaviour of heteroduplex and homoduplex. In nature, DNA 
duplex exists in a tightly associated form. As the environment becomes more 
denaturing such as in the presence of foraiamide or urea, the two strands of DNA 
molecule dissociate, i.e. melt. Different nucleotide composition will have different 
dissociation rate in the same denaturing environment. If a DNA duplex is being 
subjected to electrophoresis in a gradient of denaturation condition, at the point 
where the strands begin to separate, the rate of migration is abruptly reduced because 
ofthe more relaxed configuration ofthe duplex. If there is a mismatch in the duplex, 
the behaviour ofmelting will be altered and thus the electrophoresis profile will be 
also altered. The major drawback of this method is that if the mismatch is in the 
region such as GC rich region which has a high melting condition, then it is likely 
that the mutation is undetectable. The solution to solve this drawback is the use of a 
GC clamp that is in the end of one of primers used in PCR. The clamp region is a 
• 26 
more stable part ofthe duplex in denaturing condition (i.e. the clamp melts at a very 
high denaturing condition), allowing variations in the remaining part of duplex to be 
analysed. 
Another method relying on the electrophoretic mobility DNA molecule is the 
single stranded conformation polymorphism (SSCP). The mobility of a single strand 
DNA molecule in nondenaturing condition is not only a fimction ofits size but also 
of its nucleotide sequence that affects its conformation. DNA fragment, generated 
from PCR or restriction enzyme digestion, are run on nondenaturing polyacrylamide 
gel, with any single base change, being detectable by a mobility shift. Because the 
shift in mobility is decreasingly apparent in the fragment of increasing size, SSCP 
favours the scanning of short DNA fragment (<400 bp). However, the conditions 
(e.g. temperature and glycerol concentration) for denaturing and for the single strand 
to re-fold is very important in SSCP analysis. For any mutation, various 
experimental conditions should be examined in order to determine the most sensitive 
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condition for that mutation. Any inappropriate experimental conditions will cause the 
ambiguous mobility shift or even no mobility shift. It seems that SSCP analysis is 
suitable for screening a large number of samples of a known mutation in a given 
condition but not suitable for screening unknown mutation. Furthermore, SSCP 
cannot locate the site of mutation. 
DNA sequencing is both a mutation detection method and a fmal check of 
nature and position of lesion detected by other methods. Direct sequencing of a PCR 
product is a time-saving method. Furthermore, when looking for mutations in a 
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specific gene that are present in the genome in two alleles, then it is much more 
convenient to sequence the PCR product directly because in the site of the mutation, 
double bands will appear at the same position rather than single band. This can be a 
heterozygous mutation, i.e. two different mutated alleles or homozygous mutation 
with two same mutated alleles. The drawback of direct sequencing of PCR product 
is the,necessity to prepare single strand template for the sequencing reaction. 
Subcloning into M13 vector or plasmid with T7 DNA polymerase promoter is one of 
the methods to generate single strand DNA template, but it is time consuming. 
Moreover, because two mutated alleles are present in a genome, in order to screen 
both alleles and to exclude the error of PCR, a large number of clones have to be 
examined. Another method is the asymmetric PCR in which single strand PCR 
product is generated. However, carry-over of excess primer in PCR to sequencing 
reaction is the problem and the purification of single strand product is difficult to 
perform. The cycle sequencing is a good choice to direct sequence PCR product 
(Ruano and Kidd, 1991). The cycle sequencing reaction is similar to PCR, which 
includes three steps, the denaturing step to separate double strand template, the 
annealing step to allow annealing of specific primer to its complementary sequence, 
and finally the extension step to incorporate nucleotide. The template used in the 
cycle sequencing reaction can be single strand or double strand. Only one primer is 
used. And the product can be labelled by end-labelled primer or by incorporation of 
radioactive nucleotides. The presence of dideoxynucleotide triphosphates results in 
the creation of base specific termination. The result of temperature cycling is the 
linear amplification of the sequencing product leading to an increase of signal. 
Therefore, small amount oftemplate (<400 fmol) is required. The misincorporation 
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I of nucleotide in the previous PGR will not interfere with the signal of sequencing 
ladder as in the case of subcloning PCR product，because “error” template is only the 
minor population and signal generated from that particular “error” template will be 
covered by other signals generated from normal templates. Therefore，cycle 
sequencing is chosen to investigate the mutation in factor XII gene. 
g) About the patient with factor XII deficiency 
A patient, who is 7 years old, with factor XII deficiency has been presented 
with coagulation abnormalities in our department. From the clinical data (table 1), 
the plasma factor XII activity is less than 1%, the prothrombin time (PT) is 12.2 and 
the activated partial thromboplastin time (APTT) is 102.6. His brother has plasma 
factor XII activity 4 3 %，P T 11.2 and APTT 41.2. His mother has plasma factor XII 
activity 36%, PT 11.5 and APTT 43.6 and his father has plasma factor XII activity 
290/0, PT 10.2 and APPT 34.6. From the data of Saito (1987), the plasma factor XII 
activity is 109%i37 from 42 normal individuals. PT measures the extrinsic system 
of coagulation and normal individual has PT 10 to 14 seconds. APPT measures 
intrinsic system ofcoagulation and normal value is 30 to 40 seconds�The previous 
study of the factor XII activity in factor XII deficient patients showed that 18 
homozygotes or double heterozygotes have less that 0.01 U/ml offactor XII clotting 
activity (FXII:C) in which the normal human plasma pool was defined to contain 1 
U/ml, corresponding to 100% plasma factor XII activity (Lammle et al., 1991). The 
range ofFXII:C ofheterozygotes and normal was 0.17 - 0.68 U/ml and 0.61 _ 1.45 
U/ml respectively. By this classification, our factor XII deficient patient is 
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homozygote or double heterozygotes and his mother, his father and his brother are 
heterozygotes. 
h) Strategies used in this study 
饭 Since most of genetic lesions found in the human factor XII gene were in the 
exon 10 to exon 14 which encode the catalytic domain of factor XII protein, we first . 
focused on these exons to identify the genetic lesion in the factor XII deficient 
patient presented to our Department. Exons were amplified by polymerase chain 
reaction (PCR) using a pair of primers flanking two sequential exons and intron 
between that two exons. According to Riith and Kempter (1993)，the primers were at 
the intron-exonjunction such that a part of primer was complementary to the intron 
sequence and another part was complementary to the exon. The amplification 
products from a normal person and the factor XII deficient patient were purified and 
sequenced by cycle sequencing reaction using one of the PCR primers as sequencing 
primer. 
The sequential amplification of each and every exon from genomic DNA is 
obviously laborious on account ofthe large number of exons spreading over a large 
genomic sequence. Other than genomic DNA, cDNA reverse-transcribed from 
mRNA may be an alternative material for mutation analysis. The use of PCR 
amplified cDNA as analytical material allows the examination of many exons in a 
single experiment and at the same time the detection of splicing defect may also be 
achieved (Cooper and Krawczak, 1993a). The presence of the amplification products 
may also indicate the normal function of the regulatory region of a gene. However, 
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the accessibility ofexpressing tissue, for example liver for the coagulation factors，is 
difficult. The existence of low background level of correctly spliced mRNA 
transcripts (ectopic transcript or illegitimate transcript)of tissue-specific genes in a 
number of supposedly ‘non-expressing, tissue has been demonstrated (Chelly et al., 
1989; Sarkar and Sommer, 1989). Schloesser et al. (1995) detected factor XII 
ectopic transcript in total RNA of peripheral blood lymphocytes of a factor XII 
deficient patient. It seems that the use of RT-PCR may generate a full length or 
partial factor XII cDNA for use in screening for mutations by cycle sequencing. 




Family relateship Sex Plasma factor XII activity PT (seconds) APTT (secondiT 
=^=^^^^^M^ F W o “ 11.5 43.6 
Brother M 43%' 11.2 41.2 
Father M 29% 10.2 34.6 
Patient M <1% 12.2 102.6 
Normalrange • ^ ^ ^ ^ 
Table 1 Clinical tests of blood plasma of the factor XII deficient patient and his 
family members. The prothrombin time, PT, measures the extrinsic 
^ pathway of coagulation (factor X, V，prothrombin and fibrinogen). The 
activated prothromboplastin time, APTT, measures the intrinsic pathway of 
coagulation (factor VIII, IX，XI and XII in addition of factors common to 
both intrinsic and extrinsic pathway). 
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2. Methods and Materials 
i 
a) Genomic DNA extraction 
i 
To remove plasma, heparin-treated blood was centrifuged at 3000 rpm 4 � C 
for 10 minutes. Six ml of lysis buffer (10 mM KHCO3, 155 mM NH4Cl, 0.1 mM 
EDTA, pH8.0) was added to blood cells. The mixture oflysis buffer and blood cells 
was chilled on ice for 5 minutes prior to centrifugation at 5000 rpm 4°C for 10 
minutes. The procedures to lyse red blood cells were repeated until a cell pellet with 
white colour was obtained. To the white cell pellet, 5 ml TE buffer (10 mM Tris-
HC1, 1 mM EDTA, pH8.0) was added to resuspend the pellet by vortex and 
transferred to a new 10-ml Eppendorf tube. Then, 1 ml 10%(w/v) SDS was added 
and the mixture was incubated at 50�C ovemight to lyse cells. To precipitate protein 
and SDS, 1.7 ml 5M NaCl was added to 6 ml lysed mixture to a final concentration 
of 1.3 M and centrifuged at 5000 rpm 4°C for 10 minutes. The supernatant was 
transferred to a 10-ml Eppendorftube. To extract protein in the supernatant, equal 
volume of phenol:chloroform (1:1) was added and then centnfiiged at 5000 rpm 4°C 
for 10 minutes. The upper aqueous layer was transferred to another 10-ml Eppendorf 
tube. One more chloroform extract was performed by adding equal volume 
chloroform, mixing well and centrifliging at 5000 rpm 4°C for 10 minutes. The 
aqueous layer was transferred to a 10-ml Eppendorf tube. Equal volume of cool 
absolute ethanol was added to precipitate the genomic DNA and mixed in a nutator at 
40C for 20 minutes prior to centrifugation. DNA pellet, after centrifugation, was 
washed by 70% ethanol and then resuspended in 500 ^1 TE buffer (10 mM Tris-HCl, 
1 mM EDTA, pH8.0). DNA concentration was measured by absorbance at OD260. 
The concentration ofDNA was adjusted to 200 ng/^il at stored at 4 � C . 
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b) Polymerase chain reaction amplification 
Polymerase chain reactions of the human factor XII gene were performed in a 
final volume of 50 i^l containing 2 i^l (200 ng/^il) genomic DNA, 5 i^l 10X PCR 
buffer (200 mM Tris-HCl pH8.4, 500 mM KC1), 2 mM MgCl^, 0.2 mM dNTPs, 15 
pmol of each primer and 2.5 units of Taq DNA polymerase (Gibco BRL, USA). For 
the amplification of exon 10 to exon 14, 2.5 ^1 1% Tween-20 was added to the PCR 
reaction mixture. Amplification was carried out in a thermal cycler (MJ research): 
one cycle at 94°C 5 minutes, annealing for 1 minute at the optimal temperature for 
each primer and 72°C for 10 minutes followed by 35 cycles with denaturation at 
94°C for 1 minute, annealing for 30 seconds, and extension at 72°C for 1 minute, and 
an addition cycle with 94�C for 1 minute, annealing for 30 seconds, and TTC for 10 
minutes. 5 ^1 of PCR product was evaluated by electrophoresis on 1.5% agarose gel 
in TAE buffer containing ethidium bromide. 
After agarose gel electrophoresis, the remaining portion ofPCR product was 
purified according to Qiaxe II gel purification kit (Qiagen Inc., USA). In brief, 45 ^1 
PCR product was loaded to perform electrophoresis on 1.5% agarose gel in TAE 
buffer containing ethidium bromide. The portion of gel containing PCR product was 
excised on an UV transilluminator. To the excised gel pieces, 3 volume of Buffer 
QX1 and 10 i^l QIAEX II solution were added, and then incubated at 50�C for 10 
minutes. The mixture was centriftiged at 14000 rpm for 30 seconds. The pellet was 
resuspended in 500 i^l QX1 solution and centrifuged at 14000 rpm for 30 seconds. 
The pellet was then washed twice with 500 ^1 of Buffer PE and air-dried for 15 
minutes. The PCR product was eluted by adding 20 |il of 10 mM Tris-HCl (pH8.5) 
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and incubating at room temperature for 5 minutes prior to centrifligation. The PCR 
� products were precipitated by ammonium acetate and absolute ethanol and 
resuspended in 20 i^l distilled water. The DNA concentration was measured at 
OD260 measurement. 
c) Cycle sequencing 
V ‘ ‘ 
Cycle sequencing reaction was performed according to dsDNA cycle 
sequencing system (Gibco BRL, USA) with some modifications. The primer used 
for sequencing was end-labelled by T4 polynucleotide kinase in the fmal volume of 5 
^1 containing 5X kinase buffer (300 mM Tris-HCl pH.7.8, 50 mM MgCl^, 1 M KC1), 
1 pmol primer, 10 pmol [y-''P]-ATP (Amershem, USA) and 1 unit T4 kinase. The 
reaction was performed at 37�C for 30 minutes, and then terminated by incubation at 
55°C for 5 minutes. To the end-labelling reaction mixture, 4.5 ^1 10X Taq 
sequencing buffer [300 mM Tris-HCl pH9.0, 50 mM MgCl】，300 mM KC1, 0.5% 
(w/v) w-l], 200 fmol template (PCR product) or 50 fmol plasmid, 2.5 units Taq 
DNA polymerase and distilled water was added to a final volume of 36 ^1. 8 ^1 
prereaction mixture was pipetted to one of four tubes, each containing 2 ^1 
termination mix of either ddATP, ddCTP, ddGTP or ddTTP. The termination mix of 
dsDNA cycle sequencing system contained 100 i^M each dATP, dCTP, 7-deaza-
dGTP, dTTP and 2 mM ddATP (or 2 mM ddTTP, or 1 mM ddCTP, or 0.2 mM 
ddGTP). The final sequencing reaction of each termination dideoxynucleotide was 
10 ^1. Reaction was performed in the same thermal cycler (MJ research) used for 
PCR: denaturation at 95�C for 3 minutes followed by 40 cycles with 95�C for 30 
seconds, annealing for 30 seconds at the optimum temperature for each primer and 
• extension at lTC for 1 minutes, then 10 cycles with 95�C for 30 seconds and 70°C 1 
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minutes. Sequencing reaction was stopped by adding 5 i^l Stop solution [95% (v/v) 
formamide, 10 mM EDTA pH8.0, 0.1% (w/v) bromophenol blue and 0.1% (w/v) 
xylen cyanol]. 
The Sequencing product was heat to 95°C for 5 minutes prior to 
electrophoresis on 6% or 7% polyacrylamide gel containing 6 M urea. 
Electrophoresis was carried out in TBE buffer (0.1 M Tris-HCl, 0.1 M boric acid, 2 
mM EDTA pH8.0) at a constant power of 60 W. After several hours of 
electrophoresis, gel was dried under vacuum prior to autoradiography. 
^ 
Autoradiographic film (Kodak) was exposed to dried gel at -70°C for 18 hours to 7 
days, depending on the radioactivity ofisotope used. 
d) Restriction enzyme digestion and cloning of PCR products 
The PCR products ofintron B ofthe human factor XII gene were purified by 
Qiaxe II kit and precipitated by ammonium acetate and absolute ethanol and 
resuspended in 17.5 i^l distilled water. Enzyme digestion was performed in a final 
volume of 20 ^1 containing 2 i^l 10X digestion buffer (10 mM Tris-HCl, 5 mM 
MgCl2, 100 mM NaCl, 1 mM 2-mercaptoethanol, pH8.0 at 37°C) and 2 units of TaqI 
restriction enzyme (Amershem). The digestion product was electrophoresed on 1.5 
% agarose gel in TAE buffer containing ethidium bromide. The gel was 
photographed on an UV transilluminator. 
e) Reverse transcription and polymerase chain reaction of factor 
XII ectopic transcript 
Total cellular RNA was isolated from peripheral blood cells by using the 
RNAeasy kit. In brief, the white cells pellet was obtained according to the methods 
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used to extract genomic DNA. To the cell pellet, 350 ^1 RLT solution was added 
and homogenised by a syringe. Then, 350 i^l absolute ethanol was added to the 
homogenised solution and transferred to a column tube capped on an Eppendorf 
tube. The apparatus of column tube and Eppendorf tube was centrifuged at 10000 
rpm for 15 seconds in a desktop centrifuge. Solution collected in Eppendorf tube 
was discard. 700 ^1 RW1 solution was added to the column tube and centrifuged at 
10000 rpm for 15 seconds. The column tube was washed twice by adding 500 pl 
RPE solution and centrifuged at 10000 rpm for 15 seconds. To elute the total RNA, 
30 ^1 DEPC-treated water was added to the column tube and centrifuged at top speed 
for minute. The elution procedure was repeated to increase the yield oftotal RNA. 
The concentration oftotal RNA was measured at OD260 and OD280. 
The first strand cDNA was synthesised according to SuperScript II (Gibco 
BRL). One ^g total RNA was incubated at 70�C for 10 minutes in 12 ^1 of 200 ng 
random hexamer. Then, 4 |il 5X first strand buffer (250 mM Tris-HCl pH8.3, 375 
mM KC1, 15 mM MgCy, 2 i^l 0.1 M DTT and 1 i^l dNTP (each 10 mM) was added 
to final volume of 19 ^1 and then incubated at 25°C for 5 minutes and at 42°C for 2 
minutes. 1 i^l SuperScript II enzyme (200 U/^il) was added to the reaction mixture to 
a final volume of 20 jil. 
The PCR amplification of exon 2 to exon 4 fragment from cDNA was 
performed in 25 i^l containing PCR buffer (20 mM Tris-HCl pH8.4, 50 mM KCl)，2 
mM MgCl2, 0.2 mM dNTPs, 15 pmol RNA-2 (5'-AAG CCC CCA AGG AGC ATA 
AGT A-3,) and RNA-4 (5'-GCT CCA AAC AGT ATC CCC ATC G-3，)，2.5 units 
of Taq DNA polymerase and 1 }il of 20 i^l first strand synthesis reaction mixture. 
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Three pmol ofprimer for p-actin was added to serve as internal control. As a control, 
i 
200 ng genomic DNA from normal person was added instead of the cDNA. The 
reaction was performed with denaturation at 94�C for 3 minutes followed by 30 
cycles with 940C for 1 minute, annealing at 63°C for 1 minute and extention at TTC 
• 
for 1 minute. Electrophoresis ofthe PCR product was performed on 2% agarose gel 
in TAE buffer containing ethidium bromide. The gel was photographed on an UV 
transilluminator. RT-PCR ofpyruvate dehydrogenase (PDH) is used to evaluate the 
quality of mRNA. Primers of PDH, called PDH-F (5,-TGC GCT GCA GGT GAC 
AGT TC-3') and PDH-R (5'-CAA AGC CCA TCT CTG ATA TGG G-3'), yielded 
the PCR products of size 191 bp. The amplification of PDH was performed in a 
reaction volume of 25 i^l containing PCR buffer (20 mM Tris-HCl pH8.4, 50 mM 
KC1), 2 mM MgCl2, 0.2 mM dNTPs，15 pmol of PDH-F and PDH-R primers, 2.5 
units of Taq DNA polymerase and 1 i^l of 20 i^l first strand synthesis reaction 
mixture. The reaction was performed in the thermal cycler with the thermal profile 
same as that of the FXII exon 2-exon4, except that the annealing temperature used 
for PDH-F and PDH-R was 60°C. Electrophoresis ofPCR products were performed 
in 1.50/0 agarose gel in TAE buffer containing ethidium bromide. The gel was ‘ 
photographed on an UV transilluminator. 
f) Subcloning of 95-bp novel fragment 
The 5'-b fragment in the 5’ end flanking region of factor XII was amplified 
by using primer 5-3 and 5-4 and purified by Qiaex II kit. The purified PCR product 
was cut by PstI restriction enzyme and then electrophoresed on 2% agarose gel in 
TAE buffer containing ethidium bromide. The portion of gel containing the 
fragment size of95 bp was excised and purified by Qiaex II kit. The purified 95 bp 
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fragment was ligated to pUC18 plasmid in 10 i^l reaction mixture containing 100 ng 
vector, 400 units T4 ligase and ligase buffer (Gibco BRL). The ligation reaction was 
performed at 14�C overnight. Five i^l ligation reaction mixture was transformed to 
competent cells ofE. coli strain DH5a. Baterical cells were plated on LB agar, X-
gal and IPTG, and incubated at 37°C overnight. White colonies were picked and 
inoculate in 5 ml LB broth and streaked on LB agar plate. Mini-prep of plasmid 
from LB broth was performed according to the modified aDcaline lysis method 
paang et al., 1994). Isolated plasmid was digested by PstI restriction enzyme to 
evaluate successful cloning. Cycle sequencing reaction was performed using 50 fmol 
plasmid as template and the sequencing primer M13/pUC18 forward primer (5,-
CCCAGTCACGACGTTGTAAAACG-3'). One of 24 white colonies with 95 bp 
novel sequence inserted in pUC18 plasmid was inoculated in 20 ml LB broth and 
cultured for ovemight. Mini-prep was performed in 20 1.5-ml Eppendorftubes, each 
containing 1 ml cultured broth. Digestion of plasmid with the insert was performed 
in 100 ^1 containing buffer (5 mM Tris-HCl, 1 mM MgCl2, 10 mM NaCl and 0.1 
mM Dithioerythritol) and 2 units ofPstI and incubated at 37�C for 1 hour. 
Electrophoresis of the digestion product was performed on 2% agarose gel in TAE 
buffer containing ethidium bromide. The gel containing 95 bp novel fragment was 
excised and purified by Qiaex II kit. 
g) Gel mobility shift assay 
The 95 bp probe was end-labelled in a reaction volume of 20 i^l containing 
purified fragment, kinase buffer (50 mM imidazole-HCl pH6.4, 12 mM M g C l�，1 
mM 2-mercaptoethanol and 0.07 mM ADP), 1 unit o fT4 polynucleotide kinase and 
20 pmol [y-33p]ATP. Reaction was performed at 37�C for 1 hour. YY-1 consensus 
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oligonucleotide (Santa Cruz, USA) was end-iabelled in volume of 20 ^1 containing 
200 ng consensus oligo, kinase buffer (50 mM imidazole-HCl pH6.4, 12 mM MgCl, 
1 mM 2-mercaptoethanol and 0.07 mM ADP), 1 unit of T4 polynucleotide kinase 
. and 20 pmol [y-''P]ATP and incubated at 3 7 � C for 1 hour. 
The binding reaction was performed according to Gel Shift Assay System of 
Promega. In brief, 10 ^1 reaction mixture contained binding buffer [4% glycerol, 1 
mM MgCl,, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris-HCl pH7.5 
and 0.05 mg/ml poly(dI-dC)-(ply(dI-dC)], 1 ^1 labelling reaction mixture of 95 bp 
probe and 2 i^l HeLa cell nuclear extract. For the negative control, no HeLa cell 
nuclear extract was added to the binding reaction mixture. For the positive control, 
end-labelled YY-1 consensus oligonucleotide (27 bp) was added instead of the end-
labelled 95 bp probe. For competition assay, in addition to the end-labelled probe, 
200 ng YY-1 consensus oligo was added to compete with the 95 bp probe for the 
YY-1 transcriptional factor. For the supershift assay, 1 ^1 polyclonal antibody (1 
^g/^l) ofYY-1 protein (Santa Cruz) was added. The binding reaction was evaluated 
by electrophoresis on 6% polyacrylamide gel (acrylamide:to-acrylamide=19:l) in 
TBE buffer at a constant power of 10 W for 2 hours at room temperature. The gel 








a) Analysis of the catalytic region of the human factor XII gene 
i) Polymerase Chain Reaction ofexon 10 to exon 14 ofthe humanfactorXIIgene 
Since most ofthe non-functional factor XII proteins isolated from factor XII-
deficient patients had the mutations in the catalytic domain, our initial approach was 
to analyse the exons (10 _ 14) encoding the catalytic domain. Amplifications ofexon 
10 to exon 14 by polymerase chain reaction (PCR) were performed according to the 
method called "double-exon screening" (Riith and Kempter, 1993). Primers used in 
PCR were for any two exons in row with the intron in between them (fig 6A). Each 
primer is in the intron-exon border in which part of primer is complementary to 
intron and another part is complementary to exon. The primer sequences used to 
amplify exon 10 to exon 14 were listed in table 2. Because of the high GC 
percentage in exon 10 - 14 of factor XII gene, the amplifications of these exons by 
ordinary reaction mixture were very difficult. In order to obtain specific and 
- .. - -• • -
effective amplification, 0.05% Tween-20, which enhanced the amplification reaction, 
was added in PCR reaction mixture. The optimal conditions for amplification of 
different exons were listed in table 3 as well as the published PCR condition reported 
previously (Ruth and Kempter, 1993). Some modifications were made in our 
experiments. Amplification of exon 10 - exon 11 was performed in the reaction 
mixture containing 2 mM magnesium chloride instead of 0.5 mM (Riith and 
Kempter, 1993)，in the presence of 15% glycerol and at 55°C annealing temperature. 
Amplification of exon 11 - exon 12 was performed at same annealing temperature in 
lower concentration of magnesium chloride (2 mM instead of 4 mM in previous 
report) in the presence of 20% glycerol. Amplification of exon 12-exon 13 and 
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Fig 6. Schematic diagram ofPCR amplification of: A) exon 10 to exon 14 ofthe factor 
XII gene. B) exon 2 to exon 4 of the factor XII ectopic transcript. C) exon 14 
together with the 3, end untranslated region of the factor XII gene. D) 5’ flanking 
region ofthe factor XII gene. Arrows represent the primers. 
42 
Primer Length (bp) ^ Sequence (5 '^3 ' ) GC Calculated T . 
10a 24 TCC TCC ACA GCC TTG CCG GCG AAG 67% 80°C 
Ua 24 TCC CCG CAG r.r.C CGC ACC CGA GGA 7 9% 8 6。C 
11b 27 CAC GCA CCC AGG TCG TGC TGG TAG. CTG 7 0% 94。C 
12a 26 CG CCC GGG TTA r.CT CTG TTG CGC CTT 65% 8 6°C 
12b 27 GCA GTT GTG CCT ACC CTC GAA CTG GTG 5 9 % 8 6°C 
13a 24 GTG TTC GCA GGG GCG GAG GAA TAT 5 8 % 7 6。C 
13b 24 CTA AGA GCT CAC CTG GCA CGC ATC 58% 76°C 
14a 24 GCG TGT TTC CGA CCC AGG GTG ATT 58% 7 6。C 
14b 24 CCT GAG r.AA TCA GGA AAC GGT GTG 54% 74。C 
^XB_a 24 GAG CAC ACA GTC GGT AAG TGG CCT 58% 7 6°C 
• B - b 24 GAC AGT GAG AAC TGC AGG GAC AAC 54% 74。C 
Table 2 Sequences of primers used to amplify and sequence exon 10 to exon 14 and 
intron B ofthe human factor XII gene. Primer sequence was provided by B. 
Kempter (Kempter et al., 1993). The sequences inside the exons were 
underlined. The primer sequence was typed in 5, to 3' orientation. The 
primer name with "a" means that it was a forward primer and located at the 
beginning of the exon while the “b” means that it was a reverse primer and 
located at the end of the exon. 
* calculated Tm is determined by equation 2 * (A + T) + 4 * (G + C). 
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|Previous optimal condition (Ruth and Optimal condition 
Kempter, 1993) r ^ r 
Exons Size |Primers MgCl. A = l i n g |uiycerol MgCl^ = : = Glycerol 
(mM) Temperature (mM) Temperature 
^ " ^ i ^ ~ ^ 55。C ^ ^ _ 2 _ 55°C 1 二 
7 T T ^ " ^ ^ ^ 4 55°C _ _ 2 ^ _ ^ 55°C 20% 
12+ 13 845bp 12a/13b 1 26/27�C 15% 2 • J _ _ • 
13 + 14 426bp | l3a/14b| 4 26/27�C 2 0 � / � 2 62�C _ 
Table 3 Comparison of optimal PCR condition between the conditions reported 
by Ruth and Kempter (1993) and the conditions used in this = d y . The 
PCR primers used to amplify exon 10 to exon 14 are same. The size ot 
each product was predicted from the sequence retrieved from GenBank 







exonl3 - exon 14 were both performed in the reaction mixture absence glycerol and 
at higher annealing temperature. The optimal PCR conditions for amplification of 
exon 10 to exon 14 of the factor XII gene were listed in table 3. 
The results of PCR amplification of exon 10 - 14 were in figure 7 to 10 in 
which the normal control was amplified in parallel. The expected size of each PCR 
product was predicted from the GenBank sequence. The size of PCR product of 
exon 10 - 11 using primer 10a and 1 lb was about 620 bp and the expected size is 627 
bp (fig 7). The PCR product of exon 11 - 12 using primer 1 la and 12b was about 
400 bp and the expected product size is 385 bp (fig 8). Primer 12a and 13b amplified 
exon 12 - 13 with the expected product size 845 bp. The amplified product was 
about 850 bp (fig 9). Exon 13 -14 was amplified using primer 13a and 14b，yielding 
the PCR product size of about 430 bp (fig 10). The expected product size is 426 bp. 
The size ofal l PCR products were the same as the normal control and similar to the 
predicted size. This showed that there was no large deletion or insertion in the region 
ofexon 10 - 14 that could be detected in agarose gel electrophoresis. Furthermore, if 
there is any mutation at the exon-intron junction, the amplification will be less 
efficient because the mismatch, ifany, between primer and genomic sequence would 
cause a higher dissociation rate of primer molecules from template and lowers the 
efficiency ofamplification at same stringency ofPCR condition. However, mutation 
in exon-intron boundary was not observed in the patient because the amplification 
efficiency was the same in normal at same annealing temperature. This was 
subsequently confirmed by the cycle sequencing reaction. 
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Fig 7 PCR amplification of exon 10 - exon 11 of the factor XII gene from the 
genomic DNA of a normal person and the factor XII-deficient patient. 
Lane M\ (|)174/HaeIII marker. Lane 7: the normal person. Lane 2: the 
factor XII-deficient patient. Lane 3\ negative control. Primer: 10a and 
1 lb. 5 i^l of 50 [i\ PCR products was loaded in each lane. 
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Fig 8 PCR amplification of exon 11 - exon 12 of the factor XII gene from the 
genomic DNA of two normal persons and the factor XII-deficient 
patient. Lane M: (j>174/HaeIII marker. Lane 1 and lane 2\ two normal 
persons. Lane 3: the factor XII-deficient patient. Lane 4: negative 
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Fig 9 PCR amplification of exon 12 - exon 13 of the factor XII gene from the 
genomic DNA of a normal person and the factor XII-deficient patient. 
Lane M\ ^174/HaeIII marker. Lane 1: the normal person. Lane 2\ the 
factor XII-deficient patient. Lane 3: negative control. Primer: 12a and 
13b. 10 i^l of 50 i^l PCR products was loaded in each lane. 
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Fig 10 PCR amplification of exon 13 - exon 14 of the factor XII gene from the 
genomic DNA of a normal person and the factor XII-deficient patient. 
Lane M\ 100 bp DNA ladder marker. Lane 1: the normal person. Lane 2: 
the factor XII-deficient patient. Lane 3: negative control. Primer: 13a and 
14b. 5 i^l of 50 ^1 PCR products was loaded in each lane. 
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ii) Sequencing analysis of exon 10 to exon 14 
Gel purification of PCR products by Qiaex II kit needed an additional 
precipitation in order to remove any contaminant The manual of cycle sequencing 
kit mentioned that 50 fmol template is sufficient to generate good sequencing result. 
However, for our experience, 50 fmol of PCR products only gave very weak signal 
and 100 “ 250 fmol was the optimal amount of template used in cycle sequencing 
reaction. High concentration (>400 fmol) gave very high background signal that 
interfered with analysis of results. For sequencing plasmid carrying the insert of 
PCR fragment，50 finol template gave satisfactory results. 
• I 
Sequencing reactions were performed by using a primer that was used in the 
PCR amplification. Cycle sequencing reaction is similar to PCR that the primer 
I 
should anneal to template in each cycle in order to replicate the template. Annealing 
temperature of a primer used in the cycle sequencing reaction is different from the 
annealing temperature used in the PCR because the concentration of monovalent 
cations and magnesium chloride in sequencing reaction mixture (30 mM KC1 and 5 
mM MgCl2) is different from the PCR reaction mixture (50 mM KCl and 2 mM 
MgCl2) and glycerol was not added in the sequencing reaction mixture. Therefore, 
each primer used in cycle sequencing reaction should be optimised. The optimal 
annealing temperatures of each primer used in sequencing reaction were listed in 
table 4. Exon 10 was sequenced by primer 10a with annealing temperature of 63�C. 
Exon 11 was sequenced by primer l lawith annealing temperature o f61�C. Exon 12 
was sequenced by primer 12a with annealing temperature of 64�C. Exon 13 was 
sequenced by primer 13a with annealing temperature of 62°C. Exon 14 
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Fragment Sequencing primer Optimal annealing temperature 
Exon 10 10a 63oC 
E x o n l l 11a 610C 
Exon 12 12a 64°C 
Exon 13 13a 62�C 
Exon 14 14a 6 4 � � 
3' iuitranslated region 3-F 56oC 
. 5 ， - a 5-2 55^C 
5,-b 5-3 48�C 
5,-c 5-5 550c 
5'-d 5-7 51°C 
5 � e 5-10 60�C 
95 bp novel sequence M13/pUC18 55°C 
cloned in pUCl 8 forward primer 
, I 
Table 4 Optimal cycle sequencing reaction conditions of different region in 
the 5' flanking region, the 3, untranslated region and the exons of 
the human factor XII gene. The primers sequences were listed in 
table 2 ^nd table 5. 
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was sequenced by using primer 14a with annealing temperature of 6 4 � C The 
sequencing gel ofexon 10： exon 11, exon 12，exon 13 and exon 14 and the sequence 
read from the gel were shown in figure 11 to 15. As comparing the sequences of the 
factor XII-deficient patient to the normal person and the GenBank sequence, no 
difference was observed. 
> • ‘ 
iii) Comparison to published mutation infactor XII 
In the factor XII gene, the TGT codon in exon 14 codes for cysteine at 571 
residue of the factor XII protein. In FXII Washington D.C., the possible point 
mutation that caused the substitution of cysteine by serine was the mutation of T "> | 
A at the first base of codon TGT, or G 今 C at the second base of codon. In our 
factor XII deficient patient, TGT coding for cysteine in exon 14 was observed in the 
sequencing reaction (fig 15b). No extra band at the position of T or G was observed. 
Therefore, the patient did not have the mutation same as FXII Washington D.C. 
variant protein. In factor XII gene, CGC codon in exon 10 codes for arginine at 353 
residue. In FXII Locamo, the possible point mutation that caused the substitution of 
arginine by proline (CCC) was the mutation of G ^ C at the second base of codon 
CGC. In our patient, CGC coding for arginine in exon 10 was observed in the 
sequencing reaction (fig l lb) . No extra C band was observed at the position G. 
Therefore, the patient had neither FXII Washington D.C. nor FXII Locamo protein in 
his plasma. The mutation of G •> A at the splicing acceptor site of exon 14 in factor 
XII gene was also studied by sequencing the exon 14 of factor XII gene in our 
patient. The splicing acceptor site of exon 14 in the factpr XII deficient patient was 
the same as normal person and has the sequence of CCAGggt (fig 1 9 ) � W e could not 
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Fig 11a Cycle sequencing of exon 10 in the exon 10-11 PCR products of a normal 
person and the factor XII-deficient patient. The sequencing primer was 10a 
with 63°C annealing temperature in the cycle sequencing reaction. 
Electrophoretic time: I) 1.5 hours, II) 4 hours, III) 6 hours, in 7% sequencing 
gel. 5 i^l of 15 i^l sequencing reaction mixture was loaded in each lane, in the 
order of A, C, G, T. 7 was the sequence of the normal person. 2 was the 
sequence of the factor XII-deficient patient. 
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GenBank GCAGCCGCCTTCCCTGACCAGGAACGGCCCACTGAGCTGCGGGCAGCGGCTC 
N o r m a l G C A G C C G C C T T C C C T 7 A C C A G G A A C G G C C C A C T G A G C T G C G G G C A G C G G C T C 
P a t i e n t G C A G C C G C C T T C C C T 7 A C C A G G A A C G G C C C A C T G A G C T G C G G G C A G C G G C T C 
R K S L S S M T R _ V V G G L V A L R 
G e n B a n k C G C A A G A G T C T G T C T T C G A T G A C C C G C G T C G T T G G C G G G C T G G T G G C G C T A C 
N o r m a l C G C A A G A G T C T G T C T T C G A T G A C C C G C G T C G T T G G C G G G C T G G T G G C G C T A C 
P a t i e n t C G C A A G A G T C T G T C T T C G A T G A C C C G C G T C G T T G G C G G G C T G G T G G C G C T A C 
G A H P Y 工 A A L Y W G H S F C A 
GenBank GCGGGGCGCACCCCTACATCGCCGCGCTGTACTGGGGCCACAGTTTCTGCGC 
N o r m a l G C G ? G G C G ? ? C C C C T A C A T C G C C G C G C T G T A C T G G G G C C A C A G T T T C T G C G C 
P a t i e n t G C G ? G G C G ? ? C C C C T A C A T C G C C G C G C T G T A C T G G G G C C A C A G T T T C T G C G C 
G S L I A P C W V L T A A H C L Q 
G e n B a n k C G G C A G C C T C A T C G C C C C C T G C T G G G T G C T G A C G G C C G C T C A C T G C C T G C A G 
N o r m a l C G G C A G C C T C A T C G C C C C C T G C T G G G T G C T G A C G G C C G C T C A f i J G C C T G C A G 
P a t i e n t C G G C A G C C T C A T C G C C C C C T G C T G G G T G C T G A C G G C C G C T C A C T G C C T G C A G 
D R 
G e n B a n k G A C C G G C G A G T A C C C G C C C G C C C A G A G C C G C C C 
N o r m a l G A C C G G ^ G T 7 C C C (A/G) C C C G C C C A G A G C C G C C C 
P a t i e n t G A C C G G C G A G T 7 C C C ( A / G ) C C C G C C C A G A G C C G C C ^ 
Fig 11b Sequence of exon 10 ofthe factor XII gene from a normal person and the 
factor XII deficient patient. Both sequences of the normal person and the 
patient were compared with the sequence in GenBank. The letters above the 
GenBank sequence were the amino acid sequence of the factor XII protein. 
The kallikrein cleavage site (Arg353-Val354) in factor XII protein was 
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Fig 12a Cycle sequencing of exon 11 in exonll-12 PCR products of a normal person 
and the factor XII-deficient patient. Sequencing primer was 11a with 61°C 
annealing temperature in the cycle sequencing reaction. Electrophoretic time 







T V V L G Q E R R N H S C E P C Q 
i G e n B a n k TGACGGTGGTGCTCGGCCAGGAACGCCGTAACCACAGCTGTGAGCCGTGCCA 
i N o r m a l TGACGGTGGTGCTCGGCCAGGAACGCCGTAACCACAGCTGT7AGCCGTGCCA 
] P a t i e n t TGACGGTGGTGCTCGGCCAGGAACGCCGTAACCACAGCTGT7AGCCGTGCCA 
丨 T L A V R S Y R L H E A F S P V S 
丨 GenBank GACGTTGGCCGTGCGCTCCTACCGCTTGCACGAGGCCTTCTCGCCCGTCAGC 
N o r m a l GACGTTGGCCGTGCGCTCCTACCGCTTGCACGAGGCCTTCTCGCCC7TCAGC 
I P a t i e n t GACGTTGGCCGTGCGCTCCTACCGCTTGCACGAGGCCTTCTCGCCC7TCAGC 
1 
Y Q H D L A 
I G e n B a n k TACCAGCACGACCTGGCT 
N o r m a L 7ACCAGCACGACCTGGCT 
P a t i e n t TACCAGCACGACCTGGCT 
Fig 12b Sequence of exon 11 of the factor XII gene from a normal person and the 
factor XII deficient patient. Both sequences of the normal person and the 
patient were compared with the sequence in GenBank. ？ represents the 
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Fig 13a Cycle sequencing ofexon 12 in exonll-12 PCR products of a normal person 
and the factor XII-deficient patient. The sequencing primer was 12a with 
64°C annealing temperature in cycle sequencing reaction. Electrophoretic 
time was 1.5 hour in 7% sequencing gel. 
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D A D G S C A L L S � P Y V Q P V C 
GenBank GGATGCGGACGGCAGCTGCGCGCTCCTGTCGCCTTACGTTCAGCCGGTGTGC 
N o r m a l GGATGCGGACGGCAGCTGCGCGCTCCTGTCGCCTTACGTTCAGCCGGTGTGC 
P a t i e n t GGATGCGGACGGCAGCTGCGCGCTCCTGTCGCCTTACGTTCAGCCGGTGTGC 
L P S G A A R P S E T T L C Q V A G 
GenBank CTGCCAAGCGGCGCCGCGCGACCCTCCGAGACCACGCTCTGCCAGGTGGCCG 
N o r m a l CTGCCAAGCGGCGCCGCGCGACCCTCC?AGACCACG?TCT?CCAGGTGGCCG 
P a t i e n t CTGCCAAGCGGCGCCGCGCGACCCTCCGAGACCACGCTCTGCCAGGTGGCCG 
W G H Q 
G e n B a n k GCTGGGGCCAC 
N o r m a l G7TGGGGCCAC 
P a t i e n t GCTGGGGCCAC 
Fig 13b Sequence of exon 12 ofthe factor XII gene from a normal person and the factor 
XII deficient patient. Both sequences of the normal person and the patient were 
compared with the sequence in GenBank. The letters upside the GenBank 
sequence were the amino acid sequence of the factor XII protein. ？ represents the 
undetemined nucleotide. 
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Fig 14a Cycle sequencing ofexon 13 in exonl3-14 PCR products of a normal person and the 
factor XII-deficient patient. The sequencing primer was 13a with 62°C annealing 
temperature in cycle sequencing reaction. Electrophoretic time: I) 1.5 hour, II) 3 
hours, in 6% sequencing gel. 5 i^l of 15 i^l sequencing reaction mixture was loaded 
in each lane, in the order of T, G, C, A. 7 was the sequence of the patient. 2 was the 
sequence of THE normal person. 
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i 
s E A Q V P F L S L E R C S A P D 
i G e n B a n k GGAGGCGCAGGTACCGTTCCTCTCCCTGGAG C GCTGCTCAGCCCCGGA 
i N o r m a l GGAGGCGCAG???CCGTTCCTCTCCCTGGAG(C/T)?CTGCTCAGCCCC??A 
i P a t i e n t GGAGGCGCAG???CCGTTCCTCTCCCTGGAG C ?CTGCTCAGCCCC??A 
I 
！ V H G S S 工 L P G M L C A G F L E 
i G e n B a n k CGTGCACGGATCCTCCATCCTCCCCGGCATGCTCTGGGCAGGGTTCCTCGAG 
！ N o r m a l CGTGCAC???TCCTCCATCCTCCCCGG?ATGCTCTGCGCAGGGTTCCTCGAG 
！ P a t i e n t CGTGCAC?G?TCCTCCATCCTCCCCGG?ATGCTCTGCGCAGGGTTCCTCGAG 
i 
G G T D A C Q 
； G e n B a n k GGCGGCACCGATGCGTGCCAGGTGAGCTCT 
N o r m a l GGCGGCACCG?TGCGTGCCAGGTGAGCTCT 
P a t i e n t GGCGGCACCG7TGCGTGCCAGGTGAGCTCT 
Fig 14b Sequence of exon 13 ofthe factor XII gene from a normal person and the factor 
XII deficient patient. Both sequences ofthe normal person and the patient were 
compared with the sequence in GenBank. The letters upside the GenBank 
sequence were the amino acid sequence of the factor XII protein. ？ represents 
the undetemined nucleotide. The intron sequence was underlined. 
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Fig 15a Cycle sequencing ofexon 14 in exonl3-14 PCR products of a normal person and 
the factor XII-deficient patient. The sequencing primer was 14a with 64°C 
annealing temperature in cycle sequencing reaction. Electrophoretic time: I) 1.5 
hours, II) 3 hours, in 7% sequencing geL 5 ^ il of 15 i^l sequencing reaction 





G P L V C E D Q A A E R R L T L Q G 
GenBank GGCCCGCTGGTGTGTGAGGACCAAGCTGCAGAGCGCCGGCTCACCCTGCAAG 
N o r m a l G G C C C G C T G G T G T G T G A G G A C C A A G C T G C A G A G C G C C G G C T C A C C C T G C A A G 
P a t i e n t G G C C C G C T G G T G T G T G A G G A C C A A G C T G C A G A G C G C C G G C T C A C C C T G C A A G 
工 工 S W G S G C G D R N K P G V Y 
GenBank GCATCATCAGCTGGGGATCGGGCTGTGGTGACCGCAACAAGCCAGGCGTCTA 
N o r m a l G C A T C A T C A G C 7 G G G G A T C G G G C T G T G G T G A C C G C A A C A A G C C A G G C G T C T A 
P a t i e n t G C A T C A T C A G C 7 G G G G A T C G G G C T G T G G T G A C C G C A A C A A G C C A G G C G T C T A 
T D V A Y Y L A W 工 R E H T 
G e n B a n k C A C C G A T G T G G C C T A C T A C C T G G C C T G G A T C C G G G A G C A C A C 
N o r m a l C A C C ? A T G T G G C C T A C T A C C T ? G C C ( A / T ) 7 G A T C C G G G A G C A C A C 
P a t i e n t C A C C ? A T G T G G C C T A C T A C C T ? G C C ( A / T ) 7 G A T C C G G G A G C A C A C 
Fig 15b Sequence ofexon 14 ofthe factor XII gene from a normal person and the factor 
XII deficient patient. Both sequences of the normal person and the patient were 
compared with the sequence in GenBank. The letters upside the GenBank 
sequence were the amino acid sequence of the factor XII protein. ？ represents 
the undetemined nucleotide. The amino acid residues that thought to interact 
with the side chain of substrate were underlined (Miyata et al., 1989). 
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observe extra A band at the position G base of the acceptor splicing site of exon 14. 
Therefore, the factor XII deficient patient may has not mutation at the splicing site of 
exon 14. Furthermore, the deletion o fC nucleotide in exon 12 offactor XII gene was 
not observed in the patient (GGGGCCAC) as mentioned in the GenBank accession 
number U71278 (GGGGCAC) in which no immunoreactive factor XII protein or 
activity is detectable (fig 13). The C -> A transversion at exon 10 (accession number 
U71277 TGCATGCAG)，in which no immunoreactive protein or activity is 
detectable, was not observed iii the exon 10 of the patient (TGCCTGCAG) (fig 11). 
And G •> A transition in exon 10 (accession number U71276 CAGGACCAG), in 
which no immunoreactive protein or activity is detectable, was not observed in exon 
10 of the patient (CAGGACCGG) (fig 11). The G — A transition at exon 11 
(accession number U71275 CAGCACAAC) was also not observed in the patient 
(CAGCACGAC) (fig llb). The G 今 C transversion at exon 14 (accession number 
U71274 TGGGGATCGCG) was not observed in exon 14 of the patient 
(TGGGGATCGGG) (fig 15). 
There were two possible point mutations seen in exon 12 (Fig. 13). 
Additional sequencing reaction was performed to confirm these two mutations. 
However, the result of additional sequencing reaction (fig 16) shown that these two 
possible mutations were the artefacts of sequencing reaction. The artefacts was 
found to be due to the higher amount of template (300 fmol) used in the previous 
sequencing reaction. Furthermore, polymorphic bases were observed in the 
sequencing reaction. In the intron between exon 10 and exon 11, a polymorphic site 
of A nucleotide and G nucleotide were observed both in the normal person and the 
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PATIENT NORMAL NORMAL PATIENT 
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Fig 16 Cycle sequencing of exon 12 in exonll-12 PCR products of a normal person 
and the factor XII-deficient patient. Two possible point mutations in exon 12 
have been observed in a previous sequencing reaction (two arrows). However, 
an addition sequencing reaction confirmed that these two artefacts were due to 
the high amount of PCR product added to sequencing reaction. 
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patient. The nucleotide in GenBank sequence' at that position was G. In exon 13, a 
polymorphic T nucleotide was observed together with a C nucleotide in the normal 
person while the C nucleotide was observed in the GenBank sequence and in the 
patient. 
From the sequencing results ofexon 10 _ exon 14 of the factor XII gene in the 
factor XII deficient patient, it seemed that the defect of the patient was not located in 
the catalytic domain of the factor XII gene. Furthermore, no mutation was observed 
in the intron-exon border ofexon 10 to exon 14. Therefore, no frame shift mutation 
or missing exon due to alternative splicing site was found. This means that if the 
factor XII gene in the factor XII-deficient patient was transcribed to mRNA and then 
translated to protein, the protein would be able to be cleaved by kallikrein and the 
cleaved protein was fmctional. However, less than 1% of plasma factor XII activity 
was found in the patient. Probably, the defect was in other parts of the gene. If 
mutation is in the codon coding cysteine outside the catalytic domain, the mutant 
protein may lose its function because of the alteration of its conformation. 
Accessibility of the factor XII mRNA in lymphocytes has led to investigation on the 
possible mutation that causes factor XII deficiency in the patient in mRNA level, 
because a mutation in factor XII gene may be revealed in the mRNA. 
« 
b) Ectopic transcript of factor XII in peripheral blood lymphocytes 
Normally, factor XII mRNA can only be found in liver cells which can only 
be accessed by liver biospy. However, the ectopic transcript of factor XII in 
peripheral blood lymphocytes was reported by Schloesser et aL, 1995. They found a 
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• ‘ 
novel acceptor splice site mutation (G + C) in the exon 14 that caused a truncated 
transcript in cross reacting material negative patients. In an attempt to study the 
expression of factor XII at the transcriptional level, we tried to detect factor XII 
mRNA in peripheral blood lymphocytes by reverse transcription-polymerase chain 
reaction (RT-PCR) in the factor XII deficient patient. 
> • . 
Results ofRT-PCR offactor XIIin the peripheral blood lymphocytes of the 
normal person and the factor XII-deficient patient were shown in fig 17. The 201 bp 
PCR product was corresponding to exon 2 to exon 4 of factor XII (fig 6B and table 
5). Since there is a 3 kb intron between exon 2 and exon 3, 1 min elongation time 
did not allow Taq DNA polymerase to generate sufficient amount of products that 
can be visible by ethidium bromide staining (lane 4 in fig 17). However, RT-PCR 
products of factor XII mRNA was not detected in the patient's lymphocytes while 
factor XII mRNA was detected in normal person peripheral blood lymphocytes (fig 
17). The presence of pyruvate dehydrogenase (PDH) RT-PCR product both in 
normal person and the factor XII-deficient patient showed that the absence of FXII 
RT-PCR product may not be due to the degradation of mRNA. Therefore, we 
concluded that factor XII might not be transcribed in the factor XII-deficient patient 
or transcribed in a very low level that could not be detected by vision with ethidium 
bromide staining after amplification. The lack of ectopic transcript in the peripheral 
blood lymphocytes of the patient indicates the possibility of the liver cells not being 
able to secret factor XII protein due to deregulation of the factor XII gene 
transcriptional or translational mechanism. The mutation of factor XII gene in the 
66 
Primer Length (bp) Sequence(5'^3') GC Calcu la tedT, 
3_F 20 GCA CAA ATC TCA GGT CCA CA 50% 60°C 
3_R 20 CGG ACC CAT GAA GAA AAG AG 50% 60。C 
RNA-2 22 AAG CCC CCA AGG AGC ATA AGT A 50% 66°C 
j^A-4 22 GCT CCA AAC AGT ATC CCC ATC G 55% 68。C 
5_1 20 TCC TCT CCT GCC CTC CTC TT 60% 64°C 
5_2 20 CCC TCG CTG ACA TTT GGC TT 55% 62°C 
5_3 20 AGT TCT CAA ATG TCG TGT AA ‘ 35% 54°C 
5_4 20 ATA GGA AAA GCA AAG CAA AC 35% 5 4 � C 
5_5 20 AAT GGG GGC TGT CTT TGA GG 55% 62°C 
5-6 20 GCC CTG CCA TTC TCC TTA TT 50% 60°C 
5_7 20 TTG CAC ACC TCC CAG TTA TT 4 5 % 58。C 
5_g 20 GCA TCT TAC AAC AAT ACC CA 4 0% 5 6°C 
5_9 20 GGT GGT GGG CTC CTG TAG TC 65% 66°C 
5_10 20 AGG AAC CCC AGG AGC AGC AG 65% 66°C 
Table 5 Sequences of primers using to amplify and sequence the 3, end 
untranslated region and 5, flanking region of the human factor XII gene. 
The primer sequence was typed in 5，to 3' orientation. Primer “3-F，，and 
"3-R" were used to amplify the 3, end untranslated region. The other 10 
primers were used to amplify the 5, flanking region. The odd number after ‘ 
the hyphen means it was a forward primer while the even number means it 
was a reverse primer. 
* calculated Tm is determined by equation: 2 * (A+T) + 4 * (G + C) 
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" ^ F r a g m e n t ^ P T b ^ Annealing temperature Extension time 
— =746bT 5 ^ " ^ 63X “ 1 — 
5'-b 735 bp 5-3/5-4 55�C lmin 
5'-c 704bp 5-5/5-6 60°C lmin 
5’-d 810bp 5-7/5-8 61°C lmin 
5'-e 606bp 5-9/5-10 68°C lmin 
mRNAexon2-4 201 bp R N A - 2 ^ A - 4 63°C lmin 
� 3 ' e n d 395 bp 3-F/3-R 60�C lmin 
intronB 2994bp mTB-a>WTB-b ^ ^ ^ ^ " 
Table 6 Optimal PCR condition for amplification of different region in the 5, 
flanking region, the 3，untranslated region and the intron B of the 
human factor XII gene. The size was predicted by the sequence 
retrieved from GenBank (Accession number : X67330, M11723, 
M17466 and D83737). The extension time is the time at 7 2 � C in the 
cycles ofpolymerase chain reaction. The primers sequences were listed 
in table 2 and table 5. 
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M 1 2 3 4 
A) C ^ ^ ^ ^ | 
_ 
310bp~> H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
• 
R � M 1 2 3 
1 * 9 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m m r n m | ^ ^ ^ m m ^ ^ ^ m m m ^ ^ 
234 b p + ^ ^ ^ m ^ ^ ^ ^ ^ ^ ^ ^ ^ l 
1 9 4 b p ^ ^ ^ F ^ ^ ^ ^ ^ ^ H 
Fig 17 A) RT-PCR amplification of 200 bp factor XII exon 2-exon 4 fragment from 
mRNA of lymphocytes of a normal person and the factor XII-deficient patient. 
Lane M\ (|)174/HaeIII marker. Lane 1: the normal person. Lane 2: the factor XII-
deficient patient. Lane 3: Genomic DNA of the normal person. Lane 4: negative 
control. Primer: RNA-2 (5,-AAG CCC CCA AGG AGC ATA AGT A-3,) and 
RNA-4 (5'-GCT CCA AAC AGT ATC CCC ATC G-3,). Annealing temperature: 
63°C. 10 i^l of 50 i^l PCR products was loaded in each lane. The upper band (310 
bp) represents the P-actin served as a positive control. B) The RT-PCR 
amplification ofpyrurate dehydrogenase (PDH) from mRNA of lymphocytes o f a 
normal persona and the factor XII-deficient patient. Evaluation of the quality of 
mRNA extracted from the normal person and the patient by analysis of RT-PCR 
ofPDH gene. Lane M: (j>174/HaeIII marker. Lane 1: the normal person. Lane 2\ 
the factor XII-deficient patient. Lane 3: negative control. The product size is 
about 191 bp. The annealing temperature of the primer pair PDH-F and PDH-R is 
60°C. 10 i^l of 50 i^l PCR products was loaded in each lane. 
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patient is probably in the regions that regulate the gene expression such as the 3 kb 
long 5' flanking region which contains the promoter, enhancer and inhibitor The 
failure in detecting mRNA may also be due to rapid degradation. I fmRNA molecule 
in the cell is degraded rapidly, it would not be translated efficiently to its protein. 
Therefore，we also studied the 3’ end untranslated region which is related to the rate 
ofmRNA degradation. 
V • 
c) Analysis of 3，end untranslated region of Factor XII gene 
The 3' end untranslated region in the mRNA may contain sequences that 
affect the mRNA stability, because of either secondary structure or binding of 
specific proteins that are important for delaying or enhancing mRNA degradation. 
Any mutation that changed the secondary structure or binding sites ofproteins in that 
sequence may result in the alteration of degradation time. Undetectable cDNA may 
be due to the short life time offactor XII mRNA and low number ofi ts molecules. 
In order to investigate this possibility，exon 14 together with 150 bp 3, 
untranslated region were amplified by PCR and then sequenced by cycle sequencing 
reaction. The forward primer (3-F) wasin the intron before exon 14 and the reverse 
primer (3-R) was 10 bp downstream of 3, untranslated sequence (table 5 and fig 6C). 
The PCR amplification was performed at the annealing temperature 60°C and 
. f 
yielded product about 400 bp (fig 18). The PCR products were excised from agarose ^ 
gel and purified by Qiaex II kit, and then sequenced by cycle sequencing reaction 
using the forward primer. The annealing temperature of the forward primer in the j" 
cycle sequencing reaction was 56°C. Sequence of exon 14 and 3，untranslated region 
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M 1 2 3 塞 
603 bp _ _ > ^ ^ ^ ^ ^ ^ ^ ^ 1 
^^^^^^1 
310 bp ~ ~ > ^ ^ ^ ^ ^ ^ ^ ^ 1 
• 
Fig 18 PCR amplification of exon 14 and 3’ untranslated region of the factor XII gene 
from the genomic DNA of a normal person and the factor XII-deficient patient. 
Lane M: (|)174/HaeIII marker. Lane 1: the normal person. Lane 2\ the factor XII-
deficient patient. Lane 3: negative control. Primer: 3-F and 3-R. 5 ^1 of 50 |il 
PCR products were loaded in each lane. 
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Fig 19a Cycle sequencing of the 3, end untranslated region PCR products of a normal 
person and the factor XII-deficient patient. The sequencing primer was 3-F 
with 56°C annealing temperature in the cycle sequencing reaction. 
Electrophoretic time: I) 1.5 hour, II) 4 hours, III) 6.5 hours, IV) 9 hours, in 
6% sequencing gel. Five i^l of 15 i^l the sequencing reaction mixture was 
loaded in each lane, in the order of A, C, G，T. 7 was the sequence of normal 
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GenBank TACCTGGCCTGGATCCGGGAGCACACCGTTTCCTGATTGCTCAGGGACTCAT 
Normal TACCTGGCCTGGATCCGGGAGCACACCGTTTCCTGATTGCTCAGGGACTCAT 
P a t i e n t TACCTGGCCTGGATCCGGGAGCACACCGTTTCCTGATTGCTCAGGGACTCAT 
GenBank CTTTCCCTCCTTGGTGATTCCGCAGTGAGAGAGTGGCTGGGGCATGGAAGGC 
Normal CTTTCCCTCCTTGGTGATTCCGCAGT?AGAGAGT?GCTGGGGCATGGAAGGC 
P a t i e n t CTTTCCCTCCTTGGTGATTCCGCAGT?AGAGAGT?GGTGGGGCATGGAAGGC 
GenBank AAGATTGTGTCCCATTCCCCCAGTGCGGCCAGCTCCGCGCCAGGATGGCGCA 
Normal AAGATTGTGTCCCATTCCCCCAGTGCGGCCAGCTCCGCGCCAGGATGGCG A 
Patient AAGATTGTGTCCCATTCCCCCAGTGCGGCCAGCTCCGCGCCAGGATGGCG A 
GenBank GGAAC T CAATAAAGTGCTTTGAAAATGCTGAGAAGGAAA 
Normal GGAAC(A/T)CAATAAAGTGCTTTGAAAATGCTGAGAAGGAAA 
Patient GGAAC(A/T)CAATAAAGTGCTTTGAAAATGCTGAGAAGGAAA 
Fig 19b Sequence of exon 14 and the 3，end untranslated reigon of the factor XII 
from a normal person and the factor XII deficient patient. Both sequences of 
the normal person and the patient were compared with the sequence in 
GenBank. The letters upside the GenBank sequence were the amino acid 
sequence of the factor XII protein. The intron was underlined. The 
polyadenylation recognition site (AATAAA) was highlighted. The double-




was shown in fig 19. The sequence from the factor XII-deficient patient was 
compared to that of the normal person which sequenced in parallel with the patient, 
and also compared to the GenBank record. However, no mutation was observed. 
The acceptor splice site (AGgt) of exon 14 in the patient was the same as that of the 
normal person. The TGA stop codon was also observed in the patient. The poly(A)" 
recognition site (AATAAA) was also sequenced and no mutation was in that 
sequence ofthe patient. There was a polymorphic nucleotide of A and T found two 
bases prior to poly(A)+ recognition site in the sequence of the normal person and the 
patient. The nucleotide at that position in GenBank sequence was T. 
d) Analysis of5' flanking region ofFactor XII gene 
The 5, flanking region of factor XII gene was sequenced (Citarella et aL, 
1993) to 3000 bp upstream the initiation codon (ATG) (GenBank accession: 
X67330). By SI mapping and primer extension experiments (Cool and 
MacGillivary, 1987), five sites of transcription initiation site were identified at -49 
bp, -36 bp, -28 bp, -23 bp, -17 bp prior to AUG. This indicates that factor XII 
mRNA has a short 5, untranslated sequence (ranged from 17 bp to 49 bp). TATA 
and CAAT promoter sequence were not found in the 5, flanking region of factor XII 
gene. Three Spl binding sites (GGCGGG), which were essential for basal 
transcription of TATA-less gene, were identified in factor XII gene. The factor IX 
silencer (CCTCTCCTG), which could inhibit the gene transcription, was identified at -
-3011 bp prior to transcription initiation, site. The 5’ flanking region of factor XII 
seemed to be rich in Alu sequence. Two Alu sequences were found in -390 bp to -
75 
1100 bp while other two were found in -2126 bp to -2774 bp and in opposite 
orientation to the first two. 
In order to investigate this 3 kb long 5, region of factor XII gene, 5 pairs of 
primers were design such that the sizes of PCR amplification products were 600 bp 
to 800 bp and each fragment would have 100 bp overlapped with flanking fragments. 
The primer sequences were listed in table 5. The PCR products amplified from a pair 
of primers were named from a to e, according to the region of product in the 5， 
flanking region (fig 6D). The optimal conditions for PCR amplifications of each 
fragment were listed in table 6. The primers 5-1 and 5-2 amplified the PCR product 
called 5'-a which corresponded to region about -2300 bp to -3000 bp. The amealing 
temperature of PCR reaction was 63�C. The gel electrophoresis of PCR products 
were showed in fig 20. The expected product size was 764 bp. The PCR products 
amplified by primer 5-3 and 5-4 were called 5'-b which corresponded to region about 
_1600 bp to -2400 bp (fig 21). The annealing temperature was 55�C. The expected 
product size was 735 bp. (Actual product size was different from the predicted size 
and this will be described in the following section). 5'-b overlapped with 5'-a about 
100 bp. PCR products amplified by primer 5-5 and 5-6 were called 5'-c which 
corresponded to region about -1000 bp to -1700 bp (fig 22). The annealing 
temperature was 60°C. The expected product size was 704 bp. 5'-c overlapped with 
5'-b about 100 bp. PCR products amplified by primer 5-7 and 5-8 were called 5'-d 
which corresponded to region about -300 bp to -1100 bp (fig 23). The annealing 
temperature was 61�C. The expected product size was 810 bp. 5'-d overlapped with 
5'-c about 100 bp. PCR products amplified by primer 5-9 and 5-10 were called 5'-e 
76 
M 1 2 3 
B 3 I H I I H 
V ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 
m^^^^^^^^^^^^^^^^^^^^^^^^^^^ 
827 b p ~ > ^ ^ 2 H H | | [ | ^ ^ | 
^^^^^^^^^^^^W^^ i^^ ^^P^^^^^^ |^ 
爛 • 
Fig 20 PCR amplification of 764 bp 5'-a fragment in the 5’ flanking region of the 
human factor XII gene from the genomic DNA of a normal person and the 
factor XII-deficient patient. Lane M\ (|)174/HaeIII marker. Lane 1: normal 
person. Lane 2: factor XII-deficient patient. Lane 3: negative control. 
Primer: 5-1 and 5-2. 10 i^l of 50 i^l PCR products was loaded in each lane. 
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Fig 21 PCR amplification of the 5'-b fragment in the 5' flanking region of the 
human factor XII gene from the genomic DNA of a normal person and the 
factor XII-deficient patient. Lane M.. (j>174/HaeIII marker. Lane 7: normal 
person. Lane 2\ factor XII-deficient patient. Lane 3: negative control. 
Primer: 5-3 and 5-4. 10 ^1 of 50 ^1 PCR products was loaded in each lane. 
The expected product size was 735 bp. But the amplified products had size 
of about 850 bp. 
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Fig 22 PCR amplification of 704 bp 5'-c fragment in the 5，flanking region of the 
human factor XII gene from the genomic DNA of a normal person and the 
factor XII-deficient patient. Lane M: (j>174/HaeIII marker. Lane 1\ normal 
person. Lane 2: factor XII-deficient patient. Lane 3: negative control. 
Primer: 5-5 and 5-6. 10 i^l of 50 i^l PCR products was loaded in each lane. 
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Fig 23 PCR amplification of 810 bp 5'-d fragment in the 5，flanking region of the 
human factor XII gene from the genomic DNA of a normal person and the 
factor XII-deficient patient. Lane M: (|)174/HaeIII marker. Lane 1: normal 
person. Lane 2: factor XII-deficient patient. Lane 3: negative control. 
Primer: 5-7 and 5-8. 10 i^l of 50 ^1 PCR products was loaded in each lane. 
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• 
Fig 24 PCR amplification of 608 bp 5'-e fragment in the 5, flanking region of the 
human factor XII gene from the genomic DNA of a normal person and the 
factor XII-deficient patient. Lane M.. ^174/HaeIII marker. Lane 1: normal 
person. Lane 2\ factor XII-deficient patient. Lane 3\ negative control. 
Primer: 5-9 and 5-10. 10 ^1 of 50 i^l PCR products was loaded in each lane. 
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which corresponded to region about +80 bp to -500 bp (fig 24). The annealing 
temperature was 68°C. The expected product size was 608 bp, including 30 bp of 
exon 1. 5，-e overlapped with 5'-d about 200 bp. All the PCR products amplified by 
different pairs ofprimers have sizes similar to the sizes predicted from the GenBank 
record accession number X67330, except the 5'-b fragment which has size 100 bp 
larger than expected (this will be discussed in the following section). Since larger 
size 5'-b were found in the factor XII-deficient patient and other normal persons. 
This 100 bp insertion in 5'-b did not appear to be disease-causing. 
Sequencing analysis of the 5，flanking region was performed by cycle 
sequencing reaction. One of the primers used in PCR amplification of a fragment 
was used for sequencing reaction. The optimal annealing temperatures of each 
primer used in cycle sequencing reaction were listed in table 4. The 5'-a fragment 
was sequenced by using primer 5-2, with annealing temperature of 55�C (fig 25). 
Due to two Alu repeats found in this fragment, the problem of "false stop" was 
serious. However, by observation of same pattem in bases near “false stop，，, the 
sequence was the same between the normal control and the factor XII-deficient 
patient (fig 25b). The 5'-b fragment was sequenced by using primer 5-3, with 
annealing temperature o f 4 8 � C (fig 26). The size difference between PCR products 
and predicted size was due to 95 bp inserted in the nucleotide 829 and nucleotide 830 
(TGCAG GGGCT, numbering as in GenBank record accession number X67330). 
That 95-bp insertion was found both in the normal person and in the factor XII-
deficient patient (fig 26b). The 5,-c fragment was sequenced by using primer 5-5, 
with annealing temperature o f55�C (fig 27). The sequence of normal person and the 
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Fig 25a Cycle sequencing of 5'-a PCR products in the 5，flanking region of a normal 
person and the factor XII-deficient patient. The sequencing primer was 5-2 with 
55°C annealing temperature in the cycle sequencing reaction. Electrophoretic time: 
I) 1.5 hour, II) 4 hours, in 7% sequencing gel. Five i^l of 15 i^l sequencing 
reaction mixture was loaded in each lane, in the order of A, C, G, T. 7 was the 
sequence ofthe normal person. 2 was the sequence ofthe patient. 
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GenBank AGACCTCAAGGCAAAACTGACCATCAGAAACTGTGATAAATCATCATTAAAT 
N o r m a l A G A C C T C A A G G ? ? ? A A C T G A C C A T C A ? A A A C T G T ? A ?？ 7 A T C A T C A T？ ? A A T 
P a t i e n t A G A C C T C A A G G ? ? ? A A C T G A C C A T C A ? A A A C T G T G A ?？ 7 A T C A T C A T？ ? A A T 
GenBank nTTqTT^.^TTT^^^-^^^^'^^^-^^Ar.nCTGATTTGTTACACGACATTTGAGAA 
N o r m a l G T T G T T G C T T ? ? A G C C A C A A G T T A G G G T G A T T T G T T A C A C G A C A T T T G A G A A 
P a t i e n t G T T G T T G C T T？ 7 A G C C A C A A G T T A G G G T G A T T T G T T A C A C G A C A T T T G A G A A 
GenBank CTAGTACTGATGGATTGATTTCTCATGACTTTGAGAGCCTACATCCTAAAAC 
N o r m a l C T A G T C A T G A T G G A T T 7 A T T T C T C A T G A C T T T 7 A G A G C C T A C A T C C ？ ？ ？ ?AC 
P a t i e n t C T A G T C A T G A T G G A T T G A T T T C T C A T G A C T T T 7 A G A G C C T A C A T C C ? ?？ ? A C 
GenBank TAGAAGTATCCTTAAGACTTGGTCAGTTATGGCTAGGCACAGTGGCTCACGC 
N o r m a l T ? G A A G T A T C C T ? ? ? G A C T T G G T C A G T T A T G G C T A G G C A C A G T G G C T C A C G C 
P a t i e n t T ? G A A G T A T C C T ? ? ? G A C T T G G T C A G T T A T G G C T A G G C A C A G T G G C T C A C G C 
G e n B a n k C T G T A A T T A G C C A A C A C T C T G G G A G G C T G G G G A T C A C T T 
N o r m a l C T G T 7 A T - C C C A A C A C T C T G G G A G G C T G G G G A T C A C T T 
Patient CTGT7AT--CCCAACACTCTGGGAGGCTGGGGATCACTT 
Fig 25b Sequence of 5，-a PCR products of the 5' end flanking reigon of factor XII from a 
normal person and the factor XII deficient patient. Both sequences of the normal 
person and the patient were compared with the sequence in GenBank. ？ represents 
the undetemined nucleotide. The missed nucleotides were represented as -. The 
complementary sequence of primer 5-3 was underlined. 
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Fig 26a Cycle sequencing of 5'-b PCR products in the 5, flanking region of a normal 
person and the factor XII-deficient patient. The sequencing primer was 5-3 with 
48°C annealing temperature in the cycle sequencing reaction. Electrophoretic time: 
I) 1.5 hour, II) 4 hrs, in 7% sequencing gel. 5 ^1 of 15 jal sequencing reaction 
mixture was loaded in each lane, in the order of A, C, G, T. 7 was the sequence of 
the normal person. 2 was the sequence of the patient. The bracket indicates the 95 
bp novel sequence that was not reported in the previous report of the 5’ flanking 
region sequence and in the GenBank record (X67300). 
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GenBank ATCACCCTAACTTGTGGCTTAAAGCAACAACATTTAATGATGATTTATCACA 
N o r m a l A T C A C C C T A A C T T G T G - C T？？ ? ? G C A A C A A C A T T ? A A ? ? A ? ? ? T T T A T C A C A 
P a t i e n t A T C A C C C T A A C T T G T G - C T？？ ? ? G C A A C A A C A T T ? A A ? ? A ? ? ? T T T A T C A C A 
GenBank GTTTCTGATGGTCAGTTTTGCCTTGAGGTCTGGCATAAGATTGCAAGCCAAA 
N o r m a l GTTTC??ATGGTCAGTTTTGCCT???GGTCTTTCA?AAGATTGC?AGCCAAA 
P a t i e n t GTTTC??ATGGTCAGTTTTGCCT???GGTCTTTCA?AAGATTGC?AGCCAAA 
G e n B a n k T G T C A G C G A G G G C T G C A G 
N o r m a l T G T C A G C 7 A G G G C T G C A G T A T C C A C T T C C A A G G C A G C T T A T T C A T G T G G C T G 
P a t i e n t T G T C A G C 7 A G G G C T G C A G T A T C C A C T T C C A A G G C A G C T T A T T C A T G T G G C T G 
G e n B a n k 
N o r m a l T C C A A T T G G C A C T G G C T G T C A G C A G G G T G C T T T C C T T 7 C T C C C T A C A T G G G C 
P a t i e n t T C C A A T T G G C A C T G G C T G T C A G C A G G G T G C T T T C C T T 7 C T C C C T A C A T G G G C 
G e n B a n k G G G C T G C A T G T G T G T C C T C A C A A C A C A G T G G C T G G C T T C C T C C 
N o r m a l T T C T C T G C A G G G C T G C A T G T G T G T C C T C A C A A C A C A G T G G C T G G C T T C C T C C 
P a t i e n t T T C T C T G C A G G G C T G C A T G T G T G T C C T C A C A A C A C A G T G G C T G G C T T C C T C C 
GenBank AGAGTGAGCAACCTAAGAGACCGAGGCAGAAACTGCAATGTCTTTTATGACC 
N o r m a l A G A G T ? A G C A A C C T A A G A G A C C ? A G G C A G A A A C T G C A A T G T C T T T T A T G A C C 
P a t i e n t A G A G T ? A G C A A C C T A A G A G A C C ? A G G C A G A A A C T G C A A T G T C T T T T A T G A C C 
G e n B a n k T G G G C T 
N o r m a l T G G G C T 
P a t i e n t T G G G C T 
Fig 26b Sequence of 5'-b PCR products ofthe 5, end flanking reigon of factor XII from 
a normal person and the factor XII deficient patient. Both sequences of the 
normal person and the patient were compared with the sequence in GenBank. ？ 
represents the undetemined nucleotide. There were 95 nucleotide novel 
sequence inserted in 5'-b fragment that was not reported in the previous reported 
sequence. 
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Fig 27a Cycle sequencing of5'-c PCR products in the 5’ flanking region of a normal person 
and the factor XII-deficient patient. The sequencing primer was 5-5 with 55°C 
annealing temperature in the cycle sequencing reaction. Electrophoretic time: I) 1.5 
hour, II) 4 hours, III) 6.5 hours, in 7% sequencing gel. Five i^l o f l 5 [il sequencing 
reaction mixture was loaded in each lane, in the order of A, C, G, T. 7 was the 










Patierxt A T G T G T T C A G A C C C A C A T G C T C T G T G C T T A G T A A C C C C C G T G C A A C T T T T T T 
GenBank GCTTTCCCAAAAGTTCTGGCAAAAGTCCCAAGCTAGCACTTTAATTGGCCTA 
Normal GCTTTCCCAAAAGTTCTGGCAAAAGTCCCAAGCTAGCACTTTAATTGGCCTA 






P a t i e n t G C T C T G A T T G A C C A G A C C T A G G C C A C A T C T C T A G C C C T A G C T C T G A G G G T A G 
G e n B a n k A G T T G G C A G C A C T A G A G C C C A - G G A A G A A G T A A G A G A G G A G T C G T T G C T A A A 
Normal AGTTGGCAGCACTAGAGCCCATGGAAGAAGTAAGA7AGGAGTCGTTGCTAAA 
P a t i e n t A G T T G G C A G C A C T A G A G C C C A T G G A A G A A G T A A G A 7 A G G A G T C G T T G C T A A A 
G e n B a n k GGAAAAATCAAAGTGTCATTACCG 
N o r m a 1 GGAAAAATCAAAGTGTCATTACCG 
P a t i e n t GGAAAAATCAAAGTGTCATTACCG 
Fig 27b Sequence of 5'-c PCR products of the 5' end flanking reigon of factor XII 
from a normal person and the factor XII deficient patient. Both sequences of 
the normal person and the patient were compared with the sequence in 
GenBank. ？ represents the undetemined nucleotide. The missed nucleotide 
was represented by -. The complementary sequence of primer 5-4 was 
underlined. 
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Fig 28a Cycle sequencing of 5,-d PCR products in the 5, flanking region of a normal 
person and the factor XII-deficient patient. The sequencing primer was 5-7 
with 51°C annealing temperature in cycle sequencing reaction. Electrophoretic 
time: A) 1.5 hour, B) 4 hours, in 7% sequencing geL 5 i^l of 15 ^1 sequencing 
reaction mixture was loaded in each lane, in the order o fA, C, G, T. 7 was the 
sequence ofthe normal person. 2 was the sequence ofthe patient. 89 
G e n B a n k TTTGCACATG T AATTTAAGTCC A A A T T G T T T G A C C T T A A A A T A A G G 
N o r m a l TTTGCACATG(C/T)?ATT？7AGTCCC？7ATTGTTTGACCT？？ ？?A?？？？？ 
P a t i e n t TTTGCACATG(C/T)?ATT？7AGTCCC？7ATTGTTTGACCT？？？?A?？？？？ 
GenBank AGAATGGCAGGGCCAGGCATGGTGGCTCATACCTGTAA-CCCAGCACTTTGG 
N o r m a l ？ 7 A A T G G C A ? ? ? C C A G G C A T G G T G G C T C A T A C C T G T A A T C C C A G C A C T T T G G 
P a t i e n t ？ 7 A A T G G C A ? ? ? C C A G G C A T G G T G G C T C A T A C C T G T A A T C C C A T C A C T T T G G 
G e n B a n k GAGGCCAAGGCGGGCAGATCACGAGGTCAGGAGATCGAG A CCATCCTG 
N o r m a l GAGGCCAAGGCGGGCAGATCACGAGGTCAGG?GATC?AG(A/C)CCATCCTG 
Patient GAGGCCAAGGCGGGCAGATCACGAGGTCAGGAGATC7AG A CCATCCTG 
GenBank GCTAACACAGTGAAACCCCATCTCTACTAAAAATACAAAAAAATTAGCTGGG 
N o r m a l GCTAACACAGT？？7ACCCCATCTCTAC？？？7AATAC？？？ ？ ？-ATTAGCTGGG 
P a t i e n t GCTAACACAGT？？7ACCCCATCTCTAC？？？7AATAC??？？？-ATTAGCTGGG 
G e n B a n k CGTGGTGGCGGGTGCCTGTA TCCCAGCTACCCAGGAGGCTGAGGCAGGAGA 
N o r m a l CGTGGTGGCGGGTGCCTGTATTCCCAGCTACCCA?GAGGCTGAGGCAGG?GA 
P a t i e n t CGTGGTGGCGGGTGCCTGTATTCCCAGCTACCCAGGAGGCTGAGGCAGG7GA 
G e n B a n k ATGGCGTGAACCCGGGAGGCGTA GC TTGCAGTGAGCCA 
N o r m a l ATGGCGT7AACCCGGGAGGCGTA(C/G)TTGCAGT7AGCCA 
P a t i e n t ATGGCGT7AACCCGGGAGGCGTA(C/G/TTGCAGT7AGCCA 
Fig 28b Sequence of 5'-d PCR products of the 5, end flanking reigon of factor XII from a 
normal person and the factor XII deficient patient. Both sequences of the normal 
person and the patient were compared with the sequence in GenBank. ？ represents 
the undetemined nucleotide. The complementary sequence for primer 5-6 was 
underlined. 
90 
1 2 1 2 
: ^ ^ ^ ^ ^ j n g j ^ ^ m ^ ^ ~~BdM| '"；^» 
i ) B H i i ) # j " 
^ ^ H ^ ^ ^ ^ B m^^m""―� 
^^V"miPI^ ^^^^^^^^^^B ^^ ^^ g^^  
iHHM|^|M^^^^^^^| ^ J U ^4**¾ 她说 
vS^^^HI' - ^ i^i^  了.* 
I ^ V M J： • “ - -
^^P^^)||||^|^BjB|j|||^|. V%M%M» "^t*; 
S J T — - , ‘ ..¾^ 
^ jinii^ ^mim^n^^^^p n^np .;^ ^^  
• y P M B H f % K T " ^ ^ i ^ ‘ 
^ ^ ^ ¾ • * ? ^ � + i 4 ^ " ^ T S B . ,: ^ 〜： 
^ c 4M^^ {hbi I^mil^  二/效:.:.,二 w^ 一. '*^ 
9 ^ Z J t B ^ S » , « 
^^ ^^ * lmm^ l^PHB^  iA|[w ^^ ^ T ^^®^ i^a«rtfc 
&{^^ %《.. 
• « « P ^ _ ^mK S ^ ^ ^ 麵 靈 _ S , .'_^^^S"" ^ ^^^ *®^ ^^^ ™WF 4 ; :'^ i^ii^ :"^ f^f ^S^ 
o K «jr^MI "5 :•mm.’,,- * 
*"^^ «flLSK.JMI mm ".„.", - *^舊 
4|^ WMg' mimi^mf _Mfwmm^^^ <mm 
^ ^ ¾ ¾ ' < ; 爹 5 = _ ~ 1 
f-, *"%i i i i3*%j | -"9" ,' M _ 
r n J ^ ^ ^ S * l :^^’：： ERE 厂％ J W ^ 糖 _ ^ .喻 
L F - A 1 � , S T 1 ^ • % � 
^ S B i ^ ' ; 
Fig 29a Cycle sequencing of5'-e PCR products in 5'flanking region of a normal person 
and the factor XII-deficient patient. The sequencing primer was 5-10 with 60°C 
annealing temperature in cycle sequencing reaction. Electrophoretic time: I) 1.5 
hour. II) 4 hours, III) 6.5 hours, IV) 9 hours, in 7% sequencing gel. 5 ^1 of 15 
^1 sequencing reaction mixture was loaded in each lane, in the order ofA, C, G, 
T. 7 was the sequence of the normal person. 2 was the sequence ofthe patient. 
ERE: estrogen responsive element binding site (GGTCAAGCTGCCCT). LF-
A1: liver specific transcriptional factor Al binding site (GGTCCA). The +7 
indicates the transcription initiation site. 
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P a t i e n t C T G G T G G G G C A C A G G C T G T T T G T G G A A A G C C A A G T G G A G C A A C T T C C T T G G T 
GenBank CACCCCTTGAGGGCCGGAAAGTTGGGAGTTTGTGGGTGGGGGTCAAATGAAG 
N o r m a l C A C C C C T T G A G G G C C G G A A A G T T G G G A G T T T G T G G G T G G G G G T ? A A A T ? A A G 
Patient C A C C C C T T G A G G G C C G G A A A G T T G G G A G T T T G T G G G T G G G G G T ? A A A T ? A A G 
GenBank AGCTGGGCTCCTCCTCTCTTTTCTAGATAGTGGGACTGGAAGCAGAAGAAGG 
Normal AGCTGGGCTCCTCCTCTCTTTTCTAGATAGTGGGACTGGAAGCAGAAGAAGG 
Patient A G C T G G G C T C C T C C T C T C T T T T C T A G A T A G T G G G A C T G G A A G C A G A A G A A G G 
GenBank GACATTCTTATGCTCTGGGTCCTGTGGAGATCAGGAGGTTAAGGAGATCAAA 
Normal GACATTCTTATGCGCTGGGTCCTGTGGAGATCAGGAGGTTAAGGAGATCAAA 
P a t i e n t G A C A T T C T T A T G C T C T G G G T C C T G T G G A G A T C A G G A G G T T A A G G A G A T C A A A 
G e n B a n k G A T C A T G G G G A T C T T G G A G T C C A C T G T G A A G T G T G T T C A T T T T C T A T T G T C 
Normal GATCATGGGGATCTTGGAGTCCACTGT7AAGTGTGTTCATTTTCTATTGTC 
P a t i e n t G A T C A T G G G G A T C T T G G A G T C C A C T G T 7 A A G T G T G T T C A T T T T C T A T T G T C 
Fig 29b Sequence of 5'-e PCR products of the 5’ end flanking reigon of factor XII from 
a normal person and the factor XII deficient patient. Both sequences of the 
normal person and the patient were compared with the sequence in GenBank. 
The transcriptional initiation site (+1) was bolded and underlined. The 
complementary sequence (CAT) of start codon (ATG) was bolded. Sequence 
GGTCCA was the consensus sequence of LF-A1. Sequence 
GGTCAAGCTGCCCT was the consensus sequence ofERE. 
f 
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patient could be read clearly. However, we found some differences such as a 
nucleotide more or a nucleotide less than GenBank record. For example, there 
should be 3 Cs at nucleotidel387 to 1389 (CCATCCCTTCC). But 2 Cs instead of 3 
Cs (CCATCCTTCC) were found in sequencing reaction of the 5'-c fragment 
amplified from normal person and the patient (fig 27b). Another example was at 
nucleotide 1586 and 1587 which should be GA sequence (TTGTGATATG). But we 
found a T between G and A (TTGTGTATAT) both in the normal person and the 
patient. The 5'-d fragment was sequenced by using primer 5-7, with annealing 
temperature of 51�C (fig 28). Similar to the 5,-a, 5'-d fragment contained two Alu 
repeat. Artefacts of sequencing reaction were serious. A polymorphic nucleotide 
(C/T) was observed in the normal person and the patient (fig 28b). The nucleotide in 
GenBank sequence was T. Furthermore, a polymorphic nucleotide (A/C) was 
observed in the normal person while the C nucleotide was observed in GenBank 
sequence and in the patient. The GC nucleotides was reported in GenBank sequence, 
but C/G was observed in the normal person and the patient，instead of two 
nucleotides. The 5'-e fragment was sequenced by using primer 5-10 which was in 
exon 1 (fig 29). The annealing temperature was 60�C. The transcription initiation 
site, liver specific transcriptional factor, bind site (LF-Al，TGGACC) and estrogen 
responsive element (ERE, GGGCAGCTTGACCA) were sequenced clearly (fig 29b). 
No mutation was found in the 5，flanking region of the patient's factor XII gene. 
Although there were several differences between the sequence reading from the 
autoradiography of sequencing reaction and the GenBank record, the 5, flanking 
region of the factor XII-deficient patient and normal person were the same in the 
sequence. We could not find any mutation in this 3 kb long genomic fragment. 
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e) Analysis of Intron B 
Additional ra^/restriction enzyme cutting site in intron B was reported to be 
associated with factor XH deficiency (Bemardi et al., 1987; Bemardi et al., 1988). 
Further sequencing ofthis Taqlrtstriction fragment length polymorphism (RFLP) in 
a factor XII-deficient patient in Germany confirmed the T + C at -224 bp upstream of 
exon 3 (Hofferbert et aL, 1996). In that patient another mutation ( G + C at -8bp 
upstream of exon 1) was also identified. By RT-PCR using gene specific primer in 
exon 2 and exon 4, factor XH ectopic transcript was detected in that patient and the 
PCR product was the same size and sequence as the normal person. It was unclear 
how the T to C transition and G to C transversion could result in factor XII 
deficiency. We analysed intron B of the factor XII-deficient patient for the TaqI 
RFLP. The intron B was amplified from genomic DNA by PCR using primers at the 
intron-exon border ofexon 2 and intron-exon border of exon 3 (table 2 andtable 6). 
Since the intron B of factor XII gene is about 3000 bp long, the elongation time of 
PCR was 3 min in order to provide enough time for TaqI DNA polymerase to 
synthesise the whole region. The PCR products from a normal person and the factor 
XII-deficient patient were electrophoresised in agarose gel (fig 30). The size ofPCR 
product from the patient was similar to the normal person. After purification of PCR 
products, TaqI restriction enzyme digestion was performed. The sizes of TaqI 
digested fragment were predicted by program called WebCutter in internet (web -
address: http://firstmarktet.comyTirstmarketA:utter). The sequence of intron B 
submitted to that program was retrieved from GenBank (accession number : 
D83737). Two cutting sites of TaqI restriction enzyme were found and 3 
95 • 
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2027 bp~~• ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 1 
• 
Fig 30 PCR amplification of the 3 kb intron B of factor XII gene fromthe 
genomic DNA of two normal persons and the factor XII-deficient 
patient. Lane M: ?JHindIII+EcoRI marker. Lane 1 and 2: two normal 
persons. Lane 3: factor XII-deficient patient. Lane 4\ negative 
control. Primer: JNT-F and INT-R. 5 ^1 of 50 i^l PCR products was 
loaded in each lane. 
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Fig 31 Restriction enzyme TaqI digestion of the intron B PCR products from a 
normal person and the factor XII-deficient patient. Lane M: 
X/Hindlll+EcoRI marker. Lane 1: normal person. Lane 2: factor XII-
deficient patient. The predicted sizes of digestion products were 1513 bp, 
767 bp and 690 bp. The additional TaqI restriction site will generate two 
fragments with size of 224 bp and 1289 bp, instead of the 1513-bp 
fragment. 
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fragments with sizes of 1513 bp, 767 bp and 690 bp were generated. The additional 
TaqI restriction site would generate two fragment with size of 224 bp and 1289 bp 
instead of 1513 bp. However, gel electrophoresis pattem of the digestion of PCR 
products from normal person and the factor XII-deficient patient by TaqI restriction 
enzyme was same and the fragments generated had the size similar to predicted size 
(fig 31). Bands with sizes of224 bp and 1289 bp were not observed in the digestion 
ofthe patient's PCR product. There should not have additional 7^#restriction site in 
intron B offactor XII gene in the patient. 
f) Analysis of 5'-b PCR product 
The expected PCR product size using primer 5-3 and 5-4 is 735 bp. 
However, the product size ofPCR amplification was about 850 bp (fig 21). The size 
difference was confirmed by sequencing reaction that there was 95-bp novel 
sequence inserted between nucleotide 829 and 830 (numbering as GenBank record 
accession number X67330). We tried to amplified the same fragment from other 
normal persons. The result was shown in fig 32. In addition to 4 family members of 
the factor XII-deficient patient, genomic DNA from 4 individuals of a Pakistan 
family, 7 leukaemic patients (4 Chinese and 3 Caucasians) and 1 normal person were 
used in PCR to amplified 5'-b fragment. All gave the 850 bp product instead ofthe 
expected 735 bp product. This showed that the 850 bp product is in the normal 
genome and the 95-bp insertion is not disease-causing. When searching in GenBank, 
no similar sequence was searched. This 95-bp sequence is novel. The 95-bp novel 
insertion was cut from 5'-b PCR fragment of a normal person by PstI restriction 
enzyme and cloned into the vector pUC18 plasmid. The sequencing reaction of 
cloned vector (fig 33) confirmed the sequence of novel insertion to be: 
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Fig 32 PCR amplification of the 5'-b fragment in the 5’ flanking region of the 
human factor XII gene from the genomic DNA of normal persons and the 
family member of the factor XII-deficient patient. I) Lane M: pBR322/MspI 
marker. Lane 1: factor XII-deflcient patient. Lane 2: patient's mother. Lane 
3: patient's brother. Lane 4: patient's father. Lane 5 - 8: four individuals of 
a unrelated family. Lane 9: a normal individual (Ey). Lane 10: negative 
control. II) Lane M: pBR322/MspI marker. Lane 1: a normal individual 
(Ey). Lane 2 - 5: four unrelated individuals. Lane 6: negative control. III) 
Lane M\ c|>174/HaeIII marker. Lane 1: factor XII-deficient patient. Lane 2: 
patient's mother. Lane 3: patient's brother. Lane 4: patient's father. Lane 
5-7: three unrelated Caucasian. Lane 8: negative control. Primer: 5-3 and 5-
4. 5 i^l of 50 i^l PCR products was loaded in each lane. 
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Fig 33 Sequence of the 95-bp novel sequence in the 5'-b fragment of the 5’ end flanking 
region ofthe factor XII gene of a normal person. The 95-bp novel sequence was cut 
by FstI restriction enzyme from the 5'-b PCR product and cloned into P5^/-digested 
pUC18 plasmid. In the cycle sequencing reaction, 50 fmol of purified plasmid 
template was used. The cloned sequence was bracketed. The sequence read from 
this sequencing gel was: 
t gccTGCAGTATCCACTTCCAAGGCAGCTTATTCATGTGGCTGTCCAATTGGCACT 
G G C T S 5 K G C A G G G T G C T T T C C T T T C T C C C T A C A T G G G C T T C T C $ G C j % t a t c c a c 
The FstI cutting sites (TGCA) were highlighted. The cloned sequence was in 






where the bold sequence represents the 95-bp novel insertion. In order to know 
whether there is any protein binding site in the novel sequence, the 95-bp sequence 
was submitted to TRANSFAC searching database to search for any protein binding 
site (Website address: h t t p : / / w w w • g e n o m e • a d . j p / S I T / T F S E A R C H • h t m l ) . 
The threshold score was set to 80 point. The result was in fig 34. Several putative 
protein binding sites were found, one ofthem was YY-1. 
The YY-1, Yin Yang-1, is a ubiquitously distributed transcriptional factor 
belonging to the GLI-Kruppel class of zinc fmger proteins. Functionally, YY-1 is a 
versatile factor, being a negative regulator in some systems and a positive regulator 
in others (Shrivastava and Calame., 1994). In addition, YY-1 can form complex with 
Spl，which is a essential transcriptional factor for basal transcription of TATA-less 
gene. YY-1 activates several genes such as IgH, c-myc. Also, YY-1 represses 
several genes such as c-fos, Ig kappa, skeletal a-actin. In the c-fos promoter, the 
repression is due to 80�bending ofDNA upon YY-1 binding (Natesan and Gilman, 
1993). This bending prevents interactions between upstream activators and the basal 
transcriptional factors. However, when the orientation of the YY-1 binding site is 
reversed, YY-1 activates the c-fos promoter, probably by facilitating rather than 
preventing interaction between activators and basal transcriptional factors 
(Shrivastava and Calame，1994). Shrivastava and Calame (1994) analysed the 
different YY-1 binding sequences in different genes and concluded that the 
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h t t p : / / w w w . g e n o m e . a d . j p / S I T / T F S E A R C H . h t m l 
T F S E A R C H S e a r c h R e s u l t 
** TFSEARCH ver.1.3 ** (c)1995 Yutaka Akiyama (Kyoto Univ.) 
This simple routine searches highly correlated sequence fragments 
versus TFMATRIX transcription factor binding site profile database 
by E.Wingender, R.Knueppel, P.Dietze, H.Karas (GBF-Braunschweig). 
<Warning> Scoring scheme is so straightforward in this version. 
score = 100.0 * ('weighted sum’ - min) / (max - min) 
The score does not properly reflect statistical significance！ 
Database: TRANSFAC MATRIX TABLE, Rel. 08-05-1996 
Query: 95 bp insert (95 bases) 
Taxonomy: Vertebrate 
Threshold: 80.0 point 
TFMATRIX entries with High-scoring: 
1 TATCCACTTC CAAGGCAGCT TATTCATGTG GCTGTCCAAT TGGCACTGGC entry score 
< M00217 USF 88.6 
> M00101 CdxA 87.1 
> M00240 Nkx-2. 83.7 
> MOOlOO CdxA 83.3 
< M00199 AP-1 83.0 
> M00122 USF 82.7 
< M00122 USF 82.7 
< M00240 Nkx-2. 81.4 
< M00072 CP2 81.2 
< M00101 CdxA 80.7 
51 TGTCAGCAGG GTGCTTTCCT TTCTCCCTAC ATGGGCTTCT CTGCA entry score 
> M00053 c-Rel 87.6 
< M00059 YY1 87.3 
< M00203 GATA-X 82.7 
> M00215 SRF 81.8 
> M00052 NF-kap 80.8 
< M00141 Lyf-1 80.5 
> M00054 NF-kap 80.4 
Total 17 high-scoring sites found. 
Max score: 88.6 point, Min score: 80.4 point 
Fig 34 TFSEARCH search ofthe 95 bp novel sequence in 5'-b. The TFSEARCH program 
searched the TRANSFAC database for vertebrate transcriptional factor with the 
threshold of 80.0 point. Putative transcriptional factors that have consensus 
sequence similar to the sequence in the input data were listed with the score. The 
score, as mentioned in the program, did not reflect the statistical significance. 
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consensus sequence for YY-1 repression is CCATNTTNNNA while the consensus 
sequence for YY-1 activation is CGGCCATCTTGNCTG. The score of YY-1 in this 
novel sequence was 87.3 point. But this score did not represent any statistically 
significance. Therefore, the YY-1 binding site in this 95-bp novel sequence was 
compared to YY-1 consensus sequence manually. The YY-1 binding site found in 
the 95:bp novel sequence in 5’-b fragment is 5'-CTCCCTACATGGGCTTC-3'. The 
complementary strand for this binding site is 3'-GAGGGATGTACCCGAAG-5 ‘. 
The YY-1 core sequence CCATNTT was found in the reverse direction and with 
only one base different (ATGTACC). The consensus sequence for repression was 
also found (AGGGATGTACC). Although the YY-1 binding site was in reverse 
direction, whether it activates or represses the factor XII gene is not known. 
Moreover, at position -3011 there is a factor IX silencer which inhibits the expression 
offactor IX. Since this silencer is very far away from the transcription initiation site, 
bending induced by transcriptional factors, like YY-1, probably facilitate the 
interaction between FIX silencer and downstream enhancers and basal transcriptional 
factors. It seems that whether YY-1 protein would bind to the 95-bp novel sequence 
or not is important to understand more about the regulation of factor XII gene 
expression. The binding of YY-1 protein to this 95-bp novel sequence was studied 
by gel mobility shift assay. 
The result of gel mobility shift assay is shown in fig 35. The first lane 
contained ^^P-labelled 95-bp novel sequence cut from the cloned plasmid and no 
HeLa cell nuclear extract which contains YY-1 protein was added. Therefore, a 
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Fig 35 Gel mobility shift assay of end-labelled 95 bp novel sequence in the 5'-b 
fragment using HeLa cell nuclear extract. Lane 1: end-labelled 95 bp fragment 
without nuclease extract. Lane 2: end-labelled YY-1 consensus 
oligonucleotide. Lane 3: end-labelled 95 bp fragment together with non-
labelled YY-1 consensus oligonucleotide and HeLa cell nuclear extract. 
Primer: 10a and l lb . Lane 4: end-labelled 95 bp fragment together with anti-
YY-1 antibody and HeLa cell nuclear extract. Lane 5: end-labelled 95 bp 
fragment with HeLa cells nuclear extract. 104 
band representing the unbound 95-bp novel sequence was seen. The second lane is 
the 33p-labelled YY-1 consensus oligonucleotide (27 bp) which was purchased from 
Santa Cruz. HeLa cell nuclear extract was added to reaction mixture such that YY-1 
protein would bind to YY-1 consensus oligonucleotide. Due to the binding of YY-l 
protein to the consensus oligonucleotide, the mobility of DNA-protein complex was 
greatly reduced in a nondenaturing condition. Since the size of unbound YY-1 
consensus oligonucleotide (27 bp) is smaller than 95 bp, it was at the location far 
lower than the band observed in lane 1 and could not be seen in lane 2 � T h e bound 
consensus oligonucleotide was observed at the position upper than the unbound 95-
bp novel sequence. This revealed the successful binding of YY-1 protein in HeLa 
cell nuclear extract to the YY-1 consensus oligonucleotide in that reaction condition. 
In the third lane, unlabelled YY-1 consensus oligonucleotide was added to the 
binding reaction mixture containing ^^P-labelled 95-bp novel sequence. The 
unlabelled consensus oligonucleotide competed with labelled novel sequence for 
YY-1 protein. And the expected result was the unbound 95-bp novel sequence 
appeared at the same level as in the first lane. In fourth lane, rabbit polyclonal 
antibody which was raised against the full length YY-1 protein ofhuman origin was 
added to the binding reaction mixture containing the ^^P-labelled 95-bp novel 
sequence. The polyclonal antibody would bind to YY-1 protein and hence the 
mobility of DNA-protein-antibody complex would be larger than in the condition of 
the absence of antibody. As a result the band representing the DNA-protein-antibody 
complex should appear at the position higher than the unbound fragment. However, 
no signal was observed at the higher position. Only one band appeared at the same 







； mixture containing ^^P-labelled 95-bp novel sequence and HeLa cell nuclear extract 
:t 
only. The only band appeared at this lane was at the same level as appeared at the 
first lane and at the third lane. The binding of YY-1 to the 95-bp insertion of 5'-b 
I 
i . . 
j fragment in the 5，end flanking region of the factor XII gene was not observed in this 
in vitro experiment. 
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a) Mutations in the coding sequence of factor XII gene 
The deficiency of factor XII was firstly reported in a patient called John 
Hageman in 1955 (Ratnoff and Colopy, 1955). The following studies of factor XII 
showed that it was a first factor taking action to initiate the intrinsic pathway of 
coagulation system. Factor XII is activated by plasma kallikrein which in tum is 
converted from prekallikrein by activated factor XII enzyme. Activated factor XII 
can activate factor XI in the presence of high molecular weight kininogen. However, 
other functions offactor XII was concealed. Factor XH has the ability to initiate the 
fibrinolysis and complement system, and attract neutrophils to the site of injury. 
Factor XII may have important function in fibrinolysis because in the people with 
factor XII deficiency, they have higher risk in suffering from embolism rather than 
bleeding. In coagulation, the major initiation pathway is extrinsic pathway in which 
factor VII is the first factor. In fibrinolysis, the major initiation factor is tPA. Factor 
XII is only a initiation factor with minor role in both coagulation and fibrinolysis. 
The reason ofwhy patients with factor XII deficiency suffered from embolism rather 
than bleeding is unclear. 
Up to date, 2 variant proteins of factor XII isolated from factor XII deficient 
patients were characterised. They were called FXII Washington D.C. and FXII 
Locamo. Both protein have an amino acid substitution in the catalytic domain. FXII 
Washington D.C. had a Cys571 ^ Ser that destroyed the disulphide bridge in the 
active site and hence altered the conformation of catalytic domain. This variant 
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protein could not convert prekallikrein to kallikrein. FXII Locamo had a Arg535 — 
Pro mutation in where the arginine at position 535 and valine at 534 are the kallikrein 
cleavage site. The substitution of arginine by proline removed the cleavage of 
kallikrein and hence this variant could not be activated by kallikrein. Furthermore, G 
今 A transition at the exon-intron junction of exon 14 was reported in a factor XII 
deficient patient. This transition altered mRNA splicing site and caused one base 
shifted in the reading frame of exon 14. Since the active site of factor XII protein is 
encoded in exon 14 offactor XII gene, the frame shift mutation in exon 14 caused the 
loss of functional active site. 
We have a 7-year-old /patient who has less than 1% plasma factor XII activity 
and prolonged activated partial thromboplastin time. The activated partial 
thromboplastin time (APTT) measures the intrinsic pathway of coagulation. The 
normal time of APTT is about 30 to 40 seconds. But the APTT of the patient is 
102.6 seconds. The prothrombin time (PT), which measures the extrinsic pathway of 
coagulation, ofthe patient is 12.2 seconds. The normal range ofPT is about 10 - 14 
seconds. The patient has PT in the normal range but has prolonged APTT. Our first 
approach was to locate any mutations in exon 10 to exon 14 which codes the catalytic 
domain of factor XII. The PCR amplification were according to the method used by 
Ruth and Kempter.(1993) with small modifications. For example, according to Ruth 
and Kempter (1993), exon 12 - exon 13 was amplified by primers 12a and 13b with 
annealing temperature of 26 or 27°C, in the presence of 1 mM MgCl2 and 15% 
glycerol in the PCR reaction mixture. By our optimisation, exon 12 - exon 13 was 
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i 
j amplified by the same primers with annealing temperature of 60°C, in the presence 
i ^ 




The DNA sequence of exon 10 to exon 14 was rich in G and C and the 
i 
i 
j primers chosen for amplification were restricted to exon-intron junction. Therefore, 
:i 
the primer used in PCR amplification sometimes may lose GC% balance and may 
： 4 ‘ 
have hairpin structure or form primer dimer. For example, primer 10a and 11b both 
have hairpin loop (GCC and GGC in 10a，and GCA and TGC in l lb) and have 
primer dimer (GCG in 1 Oa and CGC in 11 b) (table 2). The presence of Tween-20 and 
glycerol in the PCR reaction mixture may enhance the efficiency of PCR. Tween-20 
is a non-ionic detergent capable to reversing the effecting of certain ionic detergent 
such as SDS which is used in genomic DNA preparation. Glycerol can lead to more 
complete denaturation of genomic DNA template and therefore increase the chance 
ofprimer annealing in the early cycles ofPCR. Furthermore, glycerol can eliminate 
secondary structure of template and primer and stabilise protein structure and thus 
has influence on the Taq DNA polymerase activity. The efficiency of PCR 
amplification of genomic sequence of exon 10 to exon 11 in the patient and normal 
person was enhanced after adding Tween-20 and glycerol. By comparison of the 
calculated annealing temperature and the optimal annealing temperature, it seemed 
that the presence of glycerol in the PCR reaction mixture could reduce the annealing 
temperatures of the primers (table 2 and table 3). The sizes of the PCR products 
amplified were predicted from the sequence record in GenBank. The actual product 
size was evaluated in agarose gel electrophoresis. No size difference between the 
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normal person and the factor XII deficient patient was observed and the size ofPCR 
product was similar to the predicted size. 
The sequence of exon 10 to exon 14 of the normal person and the factor XII 
deficient patient were compared to the mutations of factor XII gene reported 
previously. The mutation that caused the variant protein of factor, FXII Washington 
. D.C” might be due to the mutation of TGT ^ AGT (serine) or TGT ^ TCT (serine). 
However, TGT codon in exon 14, which codes for the Cys571, was observed in our 
factor XII deficient patient (fig 13b). In factor XII gene, CGC codon in exon 10 
codes for arginine at 533 residue. Mutation that caused the variant protein of factor 
XII, FXII Locamo, might be due to the mutation of CGC — CCC (proline). The 
CGC codon in exon 10 ofthe factor XII gene was observed in the patient (fig 9b). 
Therefore, the patient had neither FXII Washington D.C. nor FXII Locamo protein in 
his plasma. The previous reported mutation of G ^ A at the splicing acceptor site of 
exon 14 in factor XII gene (Schloesser et al., 1995) was not found in sequence the 
exon 14 of factor XII gene in our patient (fig 17b). The splicing acceptor site of 
exon 14 in the factor XII deficient patient was same as normal person and has the 
sequence of CCAGggt, instead of mutant sequence CCAAGgt. We could not 
observed extra A band at the position G base of the acceptor splicing site of exon 14. 
Therefore, the factor XII deficient patient may not have mutation at the splicing site 
ofexon 14. Other mutations found in exon 10 to exon 14 of the factor XII gene were 
reported to GenBank. The mutations of C + A and G -> A in the exon 10，G •> A 
in the exon 11, deletion of C in the exon 12 and G 今 C in the exon 14 were not 
observed in the sequence of factor XII gene of the patient. 
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The coding sequences of exon 10 to exon 14 of the normal person and the 
patient were the same as the GenBank sequence, except that there were two 
polymorphic nucleotide observed in the normal person and the patient. In the exon 
13, C and T nucleotides polymorphism were observed in the normal person while 
only the C nucleotide was observed in the sequence of the patient and in the 
GenBank sequence (fig 12b). This C/T polymorphism in exon 13 may not be 
disease-causing. Another polymorphism was observed in exon 14. The amino acid 
residue Trp589 was encoded by TGG codon. The sequence of AGG and TGG were 
both observed in the normal person and the patient (fig 13b). However, the 
polymorphic A nucleotide was not observed in exon 14 of the normal person and the 
patient sequenced by another sequencing reaction together with 3, end untranslated 
region (fig 17b). The additional A nucleotide in exon 14 may be due to the artefact 
of sequencing reaction. 
TaqI restriction fragment length polymorphism in factor XII intron B was 
firstly reported by Bemardi et al (1987). This RFLP was found to be associated 
with factor XII deficiency in 5 patients. The additional TaqI cutting site was not 
found in 60 unrelated normal individuals. The T a q I ^ h V in intron B was confirmed 
to be due to the change of T •> C at 224 bp upstream of exon 3. Whether this 
mutation is a linked marker for gene lesion or is itself the gene lesion responsible for 
the deficiency phenotype is unclear. We have also studied this RFLP in intron B of 
our patient. We amplified intron B of factor XII by a pair of primer flanking intron 
B, instead ofperforming restriction enzyme digestion of genomic DNA and southern 
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hybridisation. The 3 kb fragment of the intron B could be amplified by 3 minutes 
I 
I elongation time but not by 1 minute elongation time. This may be due to the rate of 
j 
I nucleotide incorporation by Taq DNA polymerase. The amplified PCR products 
I f 
1 were then digested with TaqI restriction enzyme. The sizes of restriction fragments 
I 
I were predicted by using cutting programme in World Wide Web called Webcutter 
i 
\ 
i (Web address: http://firstmarket.com/firstmarket/cutter). The sequence retrieved I i 
I from GenBank (accession number: D83737) was submitted to Webcutter. The 
i 
I • • 
I predicted fragment length by TaqI digestion were 1513 bp, 767 bp and 690 bp. 
I 
These length of fragments were similar to the agarose gel electrophoresis shown in 
fig 30. The additional TaqI cutting site in intron B will generate fragments of size 
about 220 bp and 1300 bp. However, no band with size of 220 bp and 1300 bp was 
observed in the agarose gel electrophoresis. We could not observe the TaqI 
restriction fragment length polymorphism of intron B offactor XII gene in the factor 
XII-deficient patient. The patient may not carry the TaqI RFLP that has been 
reported in 5 factor XII deficient patients. 
From the result of sequence of exon 10 to exon 14 and restriction enzyme 
cutting of TaqI in intron B of factor XII in the factor XII deficient patient, we could 
not found mutations that were reported previously in other factor XII deficient 
patients. Furthermore, the sequence of exon 10 to exon 14 of factor XII gene in the 
patient was compared to normal person and the sequence reported to GenBank. 
However, we could not find any difference in between the factor XII deficient 
patient, the normal person and sequence retrieved from GenBank. 
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b) Ectopic transcript of factor XII in lymphocytes 
In principle, cDNA analysis of mutation would be of enormous benefit 
because it would obviate the need to examine many exons individually, at the same 
time providing the means to detect splicing defects (Cooper and Krawczak, 1993a). 
•p 
The problem of large introns spreading between exons is found in mutation analysis 
using genomic DNA. For example in factor IX, eight exons are dispersed over 34 kb 
of genomic DNA and several regions must be amplified and sequenced individually 
because of the limitation on the size of fragment that can be efficiently amplified and 
sequenced. However, the entire sequence ofthe coding region may well be obtained 
from mRNA with only one amplification and sequencing. However, in practice, the 
problem of using cDNA as the material for mutation analysis is that the expressing 
tissue for many tissue-specific disease genes, for example liver for coagulation 
factors and muscle for Duchenne muscular dystrophy (DMD) gene was not easily 
available for study. 
Low background levels of correctly spliced mRNA transcript, called ectopic 
transcription or illegitimate transcription, of a tissue-specific gene in a non-tissue 
specific manner was first report on 1989 (Sarkar and Sommer, 1989; Chelly et aL, 
1989). mRNA of genes for the blue pigment, phenylalanine hydroxylase, tyrosine 
hydroxylase and factor IX were detected in blood cells, K562 cells, liver cells and 
chorionic villus cells (Sarkar and Sommer, 1989). mRNA of genes for anti-
Mullerian hormone, y(?-globin, aldolase A and factor VIII were detected in human 
fetal skin fibroblasts, hepatoma cells (Hep G2) and lymphoblasts. In these studies, 
they showed that tissue-specific genes are transcribed in non-specific tissue. In both 
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previous studies, coagulation factors , factor IX and factor VIII were transcribed not 
only in liver cells but also in blood cells and other cell types. 
The ectopic transcript could be PCR amplified after reverse transcription and 
used directly in DNA sequencing. The use of ectopic transcript in mutation analysis 
was demonstrated by the detection of an already known CGA 今 TGA transition at 
codon Arg 427 of the factor VIII gene, spanning exon 8 and exon 9, using mRNA 
from lymphocytes of a haemophilia A patient (Berg et al., 1990). Ectopic transcript 
analysis also promises to be an invaluable tool for the characterisation of defect in 
mRNA splicing process. The lesion, AAG •> AAA transition, was found to be 
occurred at the -1 position of exon 3 of antithrombin III (ATIII) gene in a patient. 
Analysis of the ectopic transcript of lymphocyte mRNA demonstrated the presence 
of abnormal size ATIII mRNA in that patient and by sequencing of cDNA, lacking 
exon 3 was identified (Berg et al., 1992). Mutation analysis by accessing ectopic 
transcript of factor XII in lymphocytes was reported on 1995 (Schloesser et aL, 
1995). In that study, the total RNA extracted from peripheral blood lymphocytes o f a 
factor XII deficient patient was used in reverse transcription and polymerase chain 
reaction. PCR products were then sequenced and the G •> A mutation at the 
acceptor splice site of exon 14 of factor XII gene has been found. This transition 
caused one base shift of the exon 14 reading frame. Ectopic transcript would seem to 
represent an ideal diagnostic tool in mutation analysis because the analytical material 
is easily obtained, same as genomic DNA, by extraction from peripheral blood 
lymphocytes, and most mutations in the coding region, including those affecting 
splicing, could be detected. 
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Detection of factor XII ectopic transcript in lymphocytes of our factor XII 
deficient patient was performed after sequencing analysis of exon 10 - exon 14 
because in the first time blood sample collection, genomic DNA was extracted but no 
total RNA was prepared. Total RNA of peripheral blood lymphocytes was obtained 
in the second time of blood sample collection. Therefore, factor XII ectopic 
transcript of the patient was studied in the time after sequencing exon 10 _ exonl4, 
The first strand cDNA was synthesised by using random hexamer. Primers flanking 
exon 2 and exon 4 ofthe size ofwere used in PCR amplification. The product of201 
bp amplified from cDNA of normal person was observed in agarose gel 
electrophoresis. However, PCR product of the factor XII deficient patient was not 
observed in the agarose gel electrophoresis stained by ethidium bromide. The 
absence of PCR product of the patient in agarose gel electrophoresis may be due to 
absence of mRNA of factor XII gene in the patient, or presence of very low amount 
offactor XII mRNA in the patient such that even though after PCR amplification, the 
amount ofproduct was not sufficient to be detected by ethidium bromide staining. 
There are many reasons to explain the presence of low amount of factor XII 
mRNA in the patient, comparing to the normal person. The reduction of synthesis of 
normal gene transcript may be due to the reduction of binding of positive regulatory 
protein (enhancer) or increase ofbinding of negative regulatory protein (repressor). It 
may also be due to the cap site mutation. Transcription of mRNA is initiated at the 
cap site (+1). An A -> G transition in the mouse y^globin gene cap site resulted in 
50% decrease in the steady level of y^globin mRNA in an in vitro transient 
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expression system (Myers et al., 1986). Another possibility is the alteration in 3，end 
untranslated region which contains the element accorded for mRNA stability or 
liability. Also, the polyadenylation recognition site (AATAAA) is in the 3， 
untranslated region. Several single base pair substitutions were known in the 
polyadenylation recognition site of the a2- (HBA2) and >^globin genes, all cause a 
relatively mild form of thalassaemia due to the reduction of Hb A � synthesis to 3 -
50/0 of the normal level (Cooper and Krawczak, 1993b). To explore this possibility, 
the 3，untranslated region of factor XII gene in the factor XII deficient patient was 
amplified by PCR and sequenced by cycle sequencing. 
c) The 3，untranslated region of factor XII gene 
The 3，end untranslated region together with exon 14 of factor XII gene in a 
normal person and the factor XII-deficient patient was amplified by using a pair of 
primers. The size ofPCR product spanning exon 14 and 3，untranslated region in the ‘ 
normal person and the patient was about 400 bp. Products were obtained both from 
the normal person and the factor XII deficient patient and no gross deletion or insert 
in the amplified fragment was observed. By cycle sequencing, the acceptor splice 
site ofexon 14 in the patient was cccagGGT and this was same as the acceptor splice 
site ofnormal person. The termination codon TGA was also read in the sequencing 
reaction of the normal person and the patient. The coding region of exon 14 of the 
patient was same as the normal person. In the 3' untranslated region，the sequence of 
the patient was same as the normal subject and the sequence retrieved from GenBank 
(Accession number: M17466). The polyadenylation recognition site of factor XII 
gene of the patient was also read as AATAAA and same as normal person. At 2 
bases upstream ofthe poly(A)+ recognition site, there should be a T base. An A band 
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was observed together with T band at the same level and the sequence read was 
(AyT)CAATAAA. Since the additional A band was also observed in the normal 
person, this polymorphic base was not considered as mutation. The additional A 
band may be due to artefact ofsequencing reaction orjust polymorphism at this base. 
d) The 5，flanking region of factor XII gene 
Another possibility of the lack of factor XII mRNA in the patient's 
lymphocytes may be due to the mutation in the expression regulatory region, i.e. 5， 
end flanking region of the gene. Mutation in regulatory region disrupts the normal 
process ofgene activation and transcription initiation, resulting in either the increase 
or decrease of the level of mRNAy'protein synthesised by altering the binding of the 
positive or negative regulatory proteins. Therefore, the 5, end flanking region of 
factor XII gene in the factor XII deficient patient was further analysed. 
The 5，end flanking region of factor XII gene up to 3000 bp upstream ofthe 
initiation codon (ATG) was reported previously (GenBank Accession number: 
X67330). By SI nuclease mapping and primer extension experiments, five sites of 
transcription initiation site were identified at >49 bp, -36 bp, -28 bp, -23 bp and -17 
bp prior to ATG (Cool and MacGillivary, 1987). This indicated that factor XII 
mRNA has a short 5，untranslated sequence, ranged from 17 to 49 bp. The TATA 
box and CCAAT sequence which were important for most gene expression were not 
found in factor XII promoter region. Three Spl binding site (GGGCGG), which was 
• 
essential for basal transcription ofTATA-box-less gene, were identified in factor XII 
gene. The factor IX silencer (CCTCTCCTG)，which could inhibit transcription of 
factor IX，was identified at -3011 bp prior to transcription initiation site. A liver 
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specific transcriptional factor, LF-A1 (TGGACC), was identified at position +30 and 
-2693. The sequence AGGGCAGCTTGACC, present at the position -44/-31, is 
homologous except for one nucleotide of the palindrome AGGTCANNNTGACC 
reported as estrogen responsive element (ERE). This ERE was found to be essential 
for factor XII expression ff"arsetti et al., 1995). In addition, three half ERE, 
AGGTCA, were found at positions -1314, -968 and -608. 
The 3 kb long 5, flanking region of factor XII gene was amplified by PCR 
using five pairs of primers. The GC content of 5' flanking region is about 48%. 
Unlike amplification ofexon 10 - exon 14, no additive such as Tween-20 or glycerol 
was added in the PCR reaction mixture，because of the about half GC content,. The 
annealing temperature ofeach primer was calculated according to the equation: 2*(A 
+ T) + 4*(G + C). After one or more trials of different annealing temperatures, the 
optimal annealing temperature of each pair of primers was similar to the calculated 
annealing temperature (table 6). For example, the calculated annealing temperature 
ofprimer 5-1 and 5-2 were 64°C and 62�C respectively and the optimised annealing 
temperature used in PCR amplification was 63�C. However, in the case of pair 5-
9/5-10, the optimised annealing temperatures were 2 � C higher than the calculated 
one. The calculated annealing temperature of 5-9 and 5-10 were 66�C and the 
optimised annealing temperature was 68�C. The higher optimised annealing 
temperature may be due to the secondary structure in the DNA sequence flanked by 
these two pairs ofprimers. There is a poly(A) sequence containing 36 A nucleotide, 
one G nucleotide and two T nucleotide (AAAAAAAAAA AAAAAAAAAA 
AAAAAAAAGA AAATTAAAA) at the position downstream of forward primer of 
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5'-e flanked by 5-9 and 5-10. The poly(A) sequence may generate secondary 
structure such that artefacts were generated in sequencing reaction and no sequence 
downstream this poly(A) sequence could be read in the sequencing reaction using 5-9 
as sequencing primer. The presence of secondary structure by this poly(A) sequence 
flanking by this pair ofprimer may result in the rise of annealing temperature. 
i 
Each pair of primers was given a specific band with size similar to predicted 
size, except the 5'-b fragment amplified by primers 5-3 and 5-4. The amplified 
fragment size of 5'-b was about 100 bp larger than the predicted size of 735 bp. 
After sequencing reaction, 95 bp was found to be inserted at the position -2238 and -
2237 (numbering as +1 at the transcription initiation site). This 95-bp insertion was 
found not only in the factor XII deficient patient but also in a normal subject. The 
95-bp sequence was submitted to GenBank to search similar sequence but no similar 
sequence was returned. Therefore, this 95-bp insertion was novel. By PCR 
amplification, the 840 bp 5'-b fragment with novel insertion could be amplified from 
other fifteen subjects, including other three family members of the factor XII 
deficient patient, a Pakistan family containing four individuals, four unrelated 
Chinese leukemic patients, three Caucasian leukaemic patients and a normal person. 
It seems that this 95-bp insertion is not disease causing and it presents in the genome 
ofnormal population. Other than this insertion, other differences between sequence 
obtained from sequencing reaction and the sequence reported previously (Citarella et 
al.，1993； GenBank Accession number X67330) have be observed. For example, at 
position -1696 to -1686, the sequence retrieved from GenBank is TTCCATCCCTT， 
but the sequence we obtained from normal person and the patient was 
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TTCCATCCTT. There was double Cs instead of triple C at that position. Another 
example is the position -1496 to 1487, the sequence retrieved from GenBank is 
ATTGTGATAT but the sequence obtained was ATTGTGTATAT�There was a 
additional T nucleotide. The TA nucleotides in the sequence corresponding to 5'-a 
ofthe 5' flanking region ofthe factor XII gene was found in the GenBank sequence 
but not found in the sequence of the normal person and the patient. However, 
because the differences were also found in normal person，we think that these 
differences were not disease-causing. Other than these differences between the 
sequence read from sequencing gel and the sequence record retrieved from GenBank, 
no differences were observed between the sequence of 5，flanking region of factor 
XII gene in the patients and the sequence of normal person and the sequence record . 
e) Other possible explanations of undetectable factor XII mRNA 
No abnormal nucleotide was found in the region of 3, end untranslated region 
and 5’ flanking region offactor XII gene in the factor XII deficient patient�There are 
other factors that cause the failure ofdetecting ofthe factor XII mRNA in peripheral 
blood lymphocytes of the patient. The first one is the error in carrying PCR 
amplification of factor XII cDNA. If there is a premature termination (nonsense 
mutation) before the complementary sequence of reverse primer (3-R at exon 4), then 
no amplification product would be observed. Furthermore, if the large intron B is not 
spliced correctly from the mature mRNA and a large portion of intron B is remained 
in the mature mRNA after mRNA processing，or a large fragment is inserted between 
exon 2 to exon 4 and it will not be spliced from mRNA, then amplification ofexon 2 
to exon 4 of factor XII cDNA will fail because of limitations in the PCR efficiency. 
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In this case，the PCR products from the patient with larger size will be detected by 
transferring the PCR product from agarose gel to a membrane and hybridising with 
an internal probe. Similarly, the PCR product amplified from the genomic DNA 
using primer RNA-2 and RNA-4 would be observed by hybridisation with internal 
probe. 
Furthermore, a nonsense mutation at the position downstream exon 4 may 
also lead to failure of detecting factor mRNA in the patient. The phenomenon that 
the closer a termination codon is to the 3,end of a gene, the higher the level of 
mRNA transcripts is likely to be, is observed in several gene with nonsense mutation 
(e.g. ^globin) (Cooper and Krawczak, 1993b). The obvious possible explanation for 
this observed effect ofnonsense mutation on mRNA metabolism is that the mRNA 
which are not completely translated are not protected properly from RNase digestion 
and therefore exhibited an higher turnover rate (Cooper and Krawczak, 1993b). 
Thus, the absence of PCR amplification product of factor XII in the patient may be 
due to a nonsense mutation near the 5, end and thus reduce the level of factor XII 
mRNA in lymphocytes. 
On the other hands, we have not analysed the 3, end flanking region of factor 
XII gene in the patient. The 3, end flanking region may contains the regulatory 
elements that are essential for normal gene expression. Any mutation in 3’ end 
flanking region may lead to the reduction of gene transcription. For example, in the 
c^thalassaemia patient, a G 今 A transition at the position 69 bp downstream the 
polyadenylation recognition site ofthe ^globin gene appeared to be responsible for 
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drastically reduction of gene expression, causing ^thalassaemia. That transition 
occurred within the consensus sequence of a er>throid-specific DNA binding protein 
called GATA-1 (Cooper and Krawczak, 1993c). Therefore, we could not exclude the 
possibility that the mutation that causes deficiency of factor XII in the patient is in 
< ；! 





I In the history of finding factor XII chromosomal location, factor XII was 
once assigned to be in the short arm of chromosome 6 (6p) because trait of factor XII 
deficiency was observed in a patient with 6p and 7q translocation�Furthermore, 
reduction in the factor XII protein level was found in a patient with chromosome 6 
short arm deletion (Pearson et aL, 1982). However, the location of factor XII gene 
was confirmed to chromosome 5 by in situ hybridisation and somatic cell hybrid 
analysis (Royle et al., 1988; Citarella et al, 1988). The assignment of factor XII to 
chromosome 5 does not exclude the existence of a locus at the short arm of 
chromosome 6 that influences the expression of factor XII gene (Tuddenham and 
Cooper, 1994c). Therefore, in the factor XII deficient patient of this study, the 
absence of PCR product representing ectopic transcription of factor XII gene may be 
due to the mutation in that locus at the short arm of chromosome 6, if that locus 
transcripts a transcriptional factor that is essential for factor XII transcription. The 
assumption is based on the observation of the amount of PCR product obtained. In 
the previous study about ectopic transcript, two rounds of PCR were used to 
amplified the ectopic transcripts of several genes, including factor IX, because the 
amount ofectopic transcript in lymphocytes is very low (Sarkar and Sommer, 1989). 
In contrast, we could detect factor XII ectopic transcript in the normal person after 




I one round of PCR amplification. Probably, a locus on the short arm of chromosome 
i 
6 may be present in the peripheral blood lymphocytes and it may enhance factor XII 
expression. And probably, this factor may also be present in liver cells to enhance 
factor XII normal transcription. This factor may probably locate at the short arm of 
chromosome 6 so that the deletion ofthis locus from the genome may results in the 
reduction offactor XII level. However, as mentioned by Sarkar and Sommer (1989), 
the quantitation of PCR product is dependent on: i) quality and quantity of RNA 
isolated, ii) efficiency ofreverse transcription which depends on multiple parameters 
including the concentration of RNA, primers as well as the particular size and 
sequence of the mRNA of interest, and iii) efficiency of PCR in which a small 
difference in efficiency may result in exponential amplification. Therefore, we 
cannot exclude the possibility that the quantity ofPCR product we obtained is due to 
the parameters listed above, rather than the relative higher level of factor XII mRNA 
in the normal subject. 
f) The 95-bp novel sequence in 5，flanking region 
The 95-bp insertion in the 5'-b amplified PCR fragment is found both in 
normal person and the factor XII deficient patient. This insertion sequence was 
found in other normal persons. Therefore, it was not considered as disease-causing. 
No homologous sequence was found in GenBank. Since this novel sequence was 
found in the 5'end flanking region of factor XII gene, the sequence has been 
submitted to a transcriptional factor database, called TRANSFAC, in Japan to search 
any putative protein binding site. The result of search shown that there are several 
putative protein binding to this novel sequence. As mentioned in the program notice, 
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the score calculated does not reflect the statistical significance. Therefore, the 
binding ofone ofthese proteins, YY-1, to the novel sequence was studied in vitro. 
YY-1 (Yin Yang-1) is a ubiquitously distributed transcriptional factor 
( 
I belonging to the GLI-Kruppel class ofzinc finger proteins. Functionally, YY-1 is a 
versatile factor, being a negative regulator in some promoter and a positive regulator 
in others (Shrivastava and Calame, 1994). YY-1 transcriptional factor represents a 
new class oftranscriptional factors that influence gene transcription by affecting the 
structure of the promoter rather than directly contacting the transcriptional 
machinery. Furthermore, the binding of YY-1 that induces DNA structure bending 
does not in itself have any function in activation or repression. Moreover, the 
bending of DNA molecule may result either in activation or repression，depending on 
the functions of factors that interact with transcriptional machinery after bending. 
For example, in c-fos promoter, YY-1 bends the promoter sequence in 8 0 � s o that an 
inhibitor binding upstream of YY-1 can interact with the basal transcriptional 
complex and hence inhibit c-fos expression (>Jatesan and Gilman, 1993). In the case 
of factor XII promoter, there is a factor IX silencer at about 3 kb apart from the 
. transcription initiation site. Probably, YY-1 binding somewhere in the promoter 
region bends DNA molecule so that factor IX silencer can interact with the 
transcriptional complex. 
The orientation found in the 95-bp novel sequence is in a reverse orientation. 
As shown in fig 33, the binding sequence of YY-1 is CTCCCTACATGGGCTTC. 
The previous published nine base consensus sequence for YY-1 binding was 
^ 124 
G/CNCCATNTT. Moreover, Shrivastava and Calame (1994) grouped the consensus 
sequence into the categories of repressor consensus (CCATNTTNNNA) and 
activator consensus (CGGCCATCTTGNCTG). The centre consensus sequence 
CCATNTT is the most highly conserved portion of the repressor consensus and 
activator consensus. The complementary sequence of the YY-1 binding sequence in 
the 95-bp novel sequence is GAAGCCCATGTAGGGAC. The centre core 
sequence of consensus CCATNTT is read with only one nucleotide mismatch 
(CCATGTA). Nevertheless, the consensus sequence as the repressor site 
(CCATNTTNNNA) is also read with only one nucleotide mismatch 
(CCATGTAGGGA). Although there is high similarity between the consensus 
• sequence of YY-1 binding site and the putativeYY-1 binding site in the 95-bp novel 
sequence, we did not know whether the YY-1 protein would bind to the 95-bp novel 
sequence in vitro and in vivo. Therefore, the gel mobility shift assay was performed. 
The gel mobility shift assay of YY-1 was performed using the 95-bp novel 
insertion as probe (fig 34). YY-1 consensus oligonucleotide (5'-
CGCTCCGCGGCCATC TTGGCGGCTGGT-3', in which the bold nucleotides 
represent the binding site o fYY-l ) is served as positive control that YY-1 protein 
can bind to its consensus binding site in the condition the binding reaction 
performed. The result of gel mobility shift assay (fig. 33) of YY-1 consensus oligo 
shown that at room temperature and in the buffer provided, YY-1 protein was 
capable to bind YY-1 binding site (CCATCTT) and therefore, the retardation of 
probe was observed in the nondenaturing polyacrylamide gel. However, YY-1 did 




I YY-1 consensus oligo. The different size of 95-bp probe and YY-1 consensus oligo i '? 
.1 
1 (27 bp) may not affect the binding of YY-1 protein because other experiment 
1 
I • • 
j demonstrated the use of different size of probe and competitors in the gel mobility 
I shift assay. For example, Ogura et aL (1990) used a 140-bp probe (-130 to +9 of 
i 
j human multidrug resistance gene) in the gel shift assay with 25 bp to 46 bp 
competitor oligo, and Andersen et aL (1990) used unlabelled 54-bp oligo to compete 
with labelled 109-bp probe. However, we cannot exclude the possibility that the size 
.i • 
j difference between the labelled probe and the consensus oligo may affect the binding 
i 
！ efficiency because other proteins may bind to DNA sequence near or overlap the 
i 
( 
YY_ 1 putative binding site such that they compete with YY-1. 
i 
i t 
However, the possibility of YY-1 binding to this 95-bp novel insertion could 
not be excluded. Since only the 95 bp cut from the PCR amplified product by Pstl 
restriction enzyme was used in gel shift assay, the effect of the flanking sequence on 
. t h e protein binding to the 95-bp insertion was not studied. The 3D conformation of 
DNA molecule may affect the binding of YY-1 to the 95-bp novel sequence. 
Furthermore, there may be some other proteins which bound to the DNA sequence 
apart from the 95-bp novel sequence and these proteins may influence YY-1 binding 
at the putative binding site of the 95-bp novel sequence. The flanking sequence of 
the 95-bp insertion may also guard the YY-1 binding. Therefore, we could not 
exclude the possibility of binding action of YY-1 in the 95-bp novel sequence. 
Furthermore, the absence ofYY-1 binding in in vitro experiment dose not imply the 
absence ofYY-1 binding in vivo. 
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The presence ofthis 95-bp novel sequence of the 5’ end flanking region of 
factor XII gene will be further studied in the normal population. Because this 95-bp 
sequence was not reported in the previous study of 5'-end flanking sequence offactor 
XII gene, it is unclear that this 95-bp sequence is polymorphic or the mistake of the 
previous sequence. Therefore, further PCR amplification of 5-b fragment from 
several normal persons, including persons from different race groups, and sequencing 
the PCR products will be performed. 
g) Technical difficulties 
DNA sequencing is both a mutation screening method and a final check of the 
nature and position ofthe lesion detected by other techniques. PCR products can be 
sequenced directly, or may be cloned into a vector such as pUC18 plasmid or M13 
phage. The subcloning of PCR products prior to sequencing reaction may generate 
clearer sequencing patterns than direct sequencing. However, it is also sensitive to 
artefactual errors introduced during PCR amplification. Therefore, subcloning is not 
applied unless there is a possible mutation. For example, there were several point 
mutations in 5'e fragment of the patient. To confirm these mutation, 5'e PCR 
products from the patient were subeloned into pUC18 plasmid. In order to overcome 
the problem ofmis-incorporation during PCR amplification, all clones with insert in 
the same orientation were mixed together and sequenced in a single reaction mixture. 
In fig 36 showed the sequence ofthe 5'e fragment of the patient generated from 40 
clones in a sequencing reaction. A clear pattem of sequencing ladder was generated 
and the possible point mutations were not observed. These possible mutation may be 
due to artefact generated during sequencing reaction. 
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Fig 36 Cycle sequencing of5'-e PCR product of the factor XII deficient patient cloned in 
pUC18 plasmid. The sequencing primer was M13/pUC18 forward primer with 
55°C annealing temperature in the cycle sequencing reaction. Electrophoretic 
time was 1.5 hour in 7% sequencing gel. 5 i^l of 15 i^l sequencing reaction 
mixture was loaded in each lane. The position LF-A1 binding site was indicated. 
The sequence obtained : 
CAGGAGCAGCAGAGCCCTCATGGCGTCCGTCCGTTGGTCCAGCTGCCTATCCAG 
GAGTCCAGATCAATAGGACTGGCC 
in which the complementary sequence (CAT) of stop codon (ATG) was 
highlighted. The LF-A1 consensus sequence was underlined. 
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Artefact of sequencing reaction was usually observed even though conditions 
of sequencing reaction was optimised. The conditions of sequencing reaction, 
including amount of template used in the sequencing reaction and annealing 
temperature ofprimers, ofeach sequencing reaction of different template and primer 
used were optimised. According to the manual of dsDNA cycle sequencing system 
purchased from Gibco BRL, the amount ofDNA used in reaction can range from 5 to 
500 foiol. For our experiences, the amount of PCR products used in sequencing 
reaction should not less than 100 fmol and not more than 400 fmol. Too low amount 
(<100 fmol) ofDNA template may result in weak signal while too high (>400 fmol) 
may result in high background signal. For sequencing the pUC plasmid, as 
mentioned in the manual, 50 fmol ofplasmid is usually used (fig 32). Furthermore, 
the quality of sequencing pattem obtained also depends on the quality of PCR 
purified. Some contaminants such as EDTA or SDS may reduce the signal of 
sequencing. Therefore, we always precipitated DNA template with ethanol and 
ammonium acetate before sequencing reaction. Besides, PCR products were purified 
by gel electrophoresis but not purified directly from PCR reaction mixture. It is 
because even though a single major PCR product is observed in agarose gel 
electrophoresis, it cannot exclude the generation of other minor products that cannot 
be observed by ethidium bromide straining. Therefore, PCR products used to 
sequencing reaction were purified from the pieces of gel excised after gel 
electrophoresis. k 
Artefacts of sequencing reaction may be sequence-specific (Howe and Ward, 
1991). The sequence TGCC may cause an artefact band in the C track at or between 
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the levels of T and G bands. Another example is the sequence GCA which may 
cause an artefactual T or C band at the level of the A band. However, these two 
sequences did not cause any artefact in the cycle sequencing reactions, probably 
because the reactions were performed at high temperature. In the cycle sequencing 
reactions performed in this study, the artefacts were often observed in the sequence 
of TAAA. For example, in the 5'-a fragment of the 5, end flanking region of the 
factor XII gene, three TAAA sequences caused strong stops in all four tracks in the 
TAA nucleotides (fig 24b). Furthermore，in the 5'-d fragment of the 5, end flanking 
region, TAAA sequences also caused strong stops in all four tracks (fig 27b). The 
sequence ofpoly(A) nucleotides also caused artefacts, as observed in the sequencing 
result of the 5'-d PCR fragment. Six As caused strong stops in all four tracks at the 
levels. 
Since different concentration of magnesium chloride (5 mM in cycle 
sequencing and 2 mM in PCR) and potassium chloride (30 mM in cycle sequencing 
and 50 mM in PCR) were used in reaction buffer, the annealing temperature of a 
primer in PCR is different from that in cycle sequencing reaction (table 4 and table 
6). For example, the primer 5-10 used in PCR has the optimised annealing 
temperature of68°C while used in cycle sequencing it has the annealing temperature 
of 60°C. It seems that the optimised annealing temperature of cycle sequencing is 
lower than that of PCR. It may be due to the concentration of potassium ion and 
magnesium ion in the sequencing buffer. However, it is not always true. For 
example, primer 10a used in PCR has the optimised annealing temperature of 55�C 
while in cycle sequencing it has the annealing temperature of 63°C. This may be 
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because additives, 0.05% Tween-20 and 15% glycerol were present in the PCR 
reaction mixture but not in cycle sequencing reaction mixture. The addition of 
glycerol may lower the annealing temperature ofaprimer. 
h) Future study 
� I n our study, no mutation was found in the exon 10 to exon 14, 5, flanking ' 
region and 3，end untranslated region of the factor XII gene in the factor XII 
deficient patient. Directions offurther study may be placed on the 3’ flanking region 
ofthe factor XII gene that may contain regulatory elements of the factor XII gene. 
As observed in 5-thalassaemia, a G ^ A transition at the GATA-1 protein binding site 
on the 3'- end ofthe 5-globin gene resulted in the great reduction of gene expression 
(Cooper and Krawczak, 1993c). Since the failure in detecting factor XII ectopic 
transcript may be due to the occurrence of nonsense mutation before exon 4, 
sequence analysis of exon 1 to exon 4 should be performed. Besides, nonsense 
mutation at the position downstream of exon 4 may also affect the amount of mRNA 
in cells. It was observed that the closer a termination codon is to the 3’ end of a 
gene, the higher the level ofmRNA transcript is likely to be (Cooper and Krawczak, 
1993b). Therefore, the sequence analysis of exons downstream of exon 4 can be 
performed to investigate this possibility�On the other hands, a locus on the short 
arm of chromosome 6 may affect the factor XII gene expression because the deletion 
ofthe short arm of chromosome 6 resulted in the reduction of factor XII level in a 
factor XII deficient patient (Pearson et aL, 1982). To further clarify such possibility, 
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Table 1 Clinical tests of blood plasma of the factor XII deficient p.32 
patient and his family members. The prothrombin time, PT, 
measures the extrinsic pathway of coagulation (factor X, V, 
prothrombin and fibrinogen). The activated 
prothromboplastin time, APTT, measures the intrinsic 
pathway of coagulation (factor VIII，IX, XI and XII in 
addition of factors common to both intrinsic and extrinsic 
pathway). 
Table 2 Sequences ofprimers used to amplify and sequence exon 10 p.43 
to exon 14 and intron B of the human factor XII gene. 
Primer sequence was provided by B. Kempter (Kempter et . 
al, 1993). The sequences inside the exons were underlined. 
The primer sequence was typed in 5, to 3, orientation. The 
primer name with “a，，means that it was a forward primer 
and located at the beginning of the exon while the "b" means 
• that it was a reverse primer and located at the end of the 
exon. 
* calculated Tm is determined by equation 2 * (A + T) + 4 * 
(G + C). 
Table 3 Comparison of optimal PCR condition between the pA4 
conditions reported by Rtlth and Kempter (1993) and the 
conditions used in this study. The PCR primers used to 
amplify exon 10 to exon 14 are same. The size of each 
‘ product was predicted from the sequence retrieved from 
GenBank (Accession number : M17466) 
Table 4 Optimal cycle sequencing reaction conditions of different p.51 
region in the 5' flanking region, the 3' untranslated region and 
the exons ofthe human factor XII gene. The primers 
sequences were listed in table 2 and table 5. 
Table 5 Sequences of primers using to amplify and sequence the 3， p.67 
end untranslated region and 5, flanking region of the human 
factor XII gene. The primer sequence was typed in 5，to 3’ 
orientation. Primer "3-F" and "3-R" were used to amplify 
the 3, end untranslated region. The other 10 primers were 
used to amplify the 5, flanking region. The odd number 
after the hyphen means it was a forward primer while the 
even number means it was a reverse primer. 
* calculated Tm is determined by equation: 2 * (A+T) + 4 * 
(G + C) 
Table 6 Optimal PCR condition for amplification of different region p.68 
in the 5, flanking region, the 3, untranslated region and the 
intron B of the human factor XII gene. The size was 
predicted by the sequence retrieved from GenBank 
(Accession number : X67330, M11723, M17466 and 
D83737). The extension time is the time at 72°C in the 
cycles of polymerase chain reaction. The primers sequences 
were listed in table 2 and table 5. 
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